

令和元年度 医学教育部講座別研究・教育課題一覧

「しおり」機能で、目次より各講座のページにジャンプします
(青字以外の講座はデータなし)

【臨床(外科)系】

- [1 . 消化器外科学 Gastroenterological Surgery](#)
- [2 . 呼吸器外科学 Thoracic Surgery](#)
- [3 . 心臓血管外科学 Cardiovascular Surgery](#)
- 4 . 乳腺・内分泌外科学 Breast and Endocrine Surgery
- 5 . 小児外科学・移植外科学 Pediatric Surgery and Transplantation
- [6 . 脳神経外科学 Neurosurgery](#)
- 7 . 整形外科学 Orthopaedic
- [8 . 産科婦人科学 Obstetrics and Gynecology](#)
- [9 . 泌尿器科学 Urology](#)
- [1 0 . 眼科学 Ophthalmology](#)
- [1 1 . 耳鼻咽喉科頭頸部外科学 Otolaryngology-Head and Neck Surgery](#)
- [1 2 . 歯科口腔外科学 Oral and Maxillofacial Surgery](#)
- [1 3 . 皮膚病態治療再建学 Dermatology and Plastic Surgery](#)
- [1 4 . 麻酔科学 Anesthesiology](#)
- 1 5 . 臨床国際協力学 International Medical Cooperation
国立病院機構熊本医療センターとの連携講座

消化器外科学講座

【研究プロジェクト名および概要】

I. 消化管領域における研究

- ・ GIST における Imatinib 耐性獲得機構の解明
- ・ 消化管癌に関与する癌代謝関連遺伝子の解明
- ・ 消化管癌と内臓脂肪、サルコペニアの関連
- ・ 癌幹細胞性維持に関わる機能の解明
- ・ 癌をとりまく微小環境の解明
- ・ 消化管癌化学療法効果予測因子の探索と臨床応用
- ・ 胃癌腹膜播腫の予防的治療戦略の確立
- ・ 胃癌における癌関連線維芽細胞 (CAF) と癌細胞との相互作用と癌進展の機序解明
- ・ 大腸癌におけるオルガノイドを用いた癌進展に寄与する関連遺伝子の解析

II. 肝・胆膵領域における研究

- ・ がん幹細胞マーカーが膵癌進展を引き起こすメカニズムの解明
- ・ 肝胆膵領域癌における腫瘍関連間質細胞の解析
- ・ 肝星細胞の癌相互作用による浸潤・転移機構の解明
- ・ 新規画像診断技術による機能的肝体積に基づいた肝切除適応基準の確立
- ・ 膵癌 CAF における細胞老化の意義と臨床応用
- ・ 肝胆膵領域癌におけるサルコペニアの臨床的意義
- ・ ex vivo 培養系を用いた薬物治療標的の探索
- ・ ミニチュアヒト肝臓を用いた肝細胞癌の浸潤転移機序の解明
- ・ 肝内胆管癌原発巣と転移巣の遺伝子発現の網羅的解析
- ・ 生体吸収性人工胆管の開発

III. 外科一般 に関する研究

- ・ 消化器癌の発育・進展に関与する癌関連遺伝子の解明
- ・ microRNA をターゲットとした消化器癌に対する新たな治療戦略の開発
- ・ 消化器癌におけるエピゲノム変化の網羅的解析
- ・ 消化器癌における免疫チェックポイント機構の解明
- ・ 消化器癌における腸内細菌叢の解析
- ・ がん代謝が消化器癌に及ぼす生理学的意義の解明

【教職員・医員および大学院生】

| | |
|---------------------|-------|
| 教授 | 馬場 秀夫 |
| 准教授 | 石河 隆敏 |
| 准教授 | 近本 亮 |
| 特任准教授 | 吉田 直也 |
| 准教授 | 山下 洋市 |
| 講師 | 宮本 裕士 |
| 特任講師 | 馬場 祥史 |
| 助教 | 岩上 志朗 |
| 診療講師 | 林 洋光 |
| 特任准教授 | 石本 崇胤 |
| 助教 | 岩槻 政晃 |
| 助教 | 今井 克憲 |
| 特任助教 | 長井 洋平 |
| 助教 | 日吉 幸晴 |
| 特任助教 | 山村 謙介 |
| 助教 | 武山 秀晶 |
| 医員 | |
| 大学院生 (4 年生) | |
| 大学院生 (3 年生) | |
| 大学院生 (2 年生) | |
| 大学院生 (1 年生・社会人大学院生) | |
| 外国人客員研究員 | |

【メールアドレス】

| |
|---|
| hdobaba@kumamoto-u.ac.jp |
| ishiko@kumamoto-u.ac.jp |
| chika@kumamoto-u.ac.jp |
| nyoshida@kumamoto-u.ac.jp |
| y-yama@kumamoto-u.ac.jp |
| miyamotoyuji@kumamoto-u.ac.jp |
| y-baba@kumamoto-u.ac.jp |
| s-iwagami@kumamoto-u.ac.jp |
| hhayasi@kumamoto-u.ac.jp |
| taka1516@kumamoto-u.ac.jp |
| maiwa217@kumamoto-u.ac.jp |
| katsuimai@hotmail.com |
| naga1020@kumamoto-u.ac.jp |
| yukiharu@kumamoto-u.ac.jp |
| kensukeyamato711@yahoo.co.jp |
| hideaki_4921@yahoo.co.jp |
| 江藤 弘二郎、原田 和人、宮田 辰徳、徳永 竜馬、東 孝暁 |
| 内原 智幸、伊東山 瑠美、岡留 一雄、坂本 悠樹、大徳 暢哉、 |
| 中尾 陽佑、山下 晃平、遊佐 俊彦、安田 忠仁、Rebecca Kalikawe、 |
| 織田 枝里 |
| 秋山 貴彦、上村 紀雄、北村 文優、野元 大地、夏 跃超、 |
| 布鲁克 |
| 松村 和季、山根 大侍、森永 剛司、付 凌峰、胡 熙晨 |
| 魏 峰 |
| 劉 洋、Hatem El-mezayen |

【研究プロジェクト】

| | | |
|----|-----|-------------|
| I | II | III (研究の統括) |
| II | III | |
| II | III | |
| I | III | |
| II | III | |
| I | III | |
| I | III | |
| II | III | |
| I | II | III |
| I | III | |
| II | III | |
| II | III | |

【連絡先】 電話: 096-373-5211 Fax: 096-371-4378

【ホームページ】 <http://www2.kuh.kumamoto-u.ac.jp/shoukakigeka/>

【特殊技術】

1. Pyrosequencing 法を用いた遺伝子解析
2. 腹膜播腫に対する遺伝子治療
3. 食道・胃・大腸癌に対する完全鏡視下手術
4. 腹腔鏡(補助)下 肝・膵切除

【英文論文】

1. Wong GS, Zhou J, Liu JB, Wu Z, Xu X, Li T, Xu D, Schumacher SE, Puschhof J, McFarland J, Zou C, Dulak A, Henderson L, Xu P, O'Day E, Rendak R, Liao WL, Cecchi F, Hembrough T, Schwartz S, Szeto C, Rustgi AK, Wong KK, Diehl JA, Jensen K, Graziano F, Ruzzo A, Fereshetian S, Mertins P, Carr SA, Beroukhim R, Nakamura K, Oki E, Watanabe M, Baba H, Imamura Y, Catenacci D, Bass AJ: Targeting wild-type KRAS-amplified gastroesophageal cancer through combined MEK and SHP2 inhibition. *Nat Med* 24(7):968-977, 2018.
2. Wong GS, Zhou J, Bin Liu J, Wu Z, Xu X, Li T, Xu D, Schumacher SE, Puschhof J, McFarland J, Zou C, Dulak A, Henderson L, Xu P, O'Day E, Rendak R, Liao WL, Cecchi F, Hembrough T, Schwartz S, Szeto C, Rustgi AK, Wong KK, Diehl JA, Jensen K, Graziano F, Ruzzo A, Fereshetian S, Mertins P, Carr SA, Beroukhim R, Nakamura K, Oki E, Watanabe M, Baba H, Imamura Y, Catenacci D, Bass AJ: Author Correction: Targeting wild-type KRAS-amplified gastroesophageal cancer through combined MEK and SHP2 inhibition. *Nat Med* 24(10):1627, 2018.
3. Canadas I, Thummalapalli R, Kim JW, Kitajima S, Jenkins RW, Christensen CL, Campisi M, Kuang Y, Zhang Y, Gjini E, Zhang G, Tian T, Sen DR, Miao D, Imamura Y, Thai T, Piel B, Terai H, Aref AR, Hagan T, Koyama S, Watanabe M, Baba H, Adeni AE, Lydon CA, Tamayo P, Wei Z, Herlyn M, Barbie TU, Uppaluri R, Sholl LM, Sicinska E, Sands J, Rodig S, Wong KK, Paweletz CP, Watanabe H, Barbie DA: Tumor innate immunity primed by specific interferon-stimulated endogenous retroviruses. *Nat Med* 24(8):1143-1150, 2018.
4. Pectasides E, Stachler MD, Derks S, Liu Y, Maron S, Islam M, Alpert L, Kwak H, Kindler H, Polite B, Sharma MR, Allen K, O'Day E, Lomnicki S, Maranto M, Kanteti R, Fitzpatrick C, Weber C, Setia N, Xiao SY, Hart J, Nagy RJ, Kim KM, Choi MG, Min BH, Nason KS, O'Keefe L, Watanabe M, Baba H, Lanman R, Agoston AT, Oh DJ, Dunford A, Thorner AR, Ducar MD, Wollison BM, Coleman HA, Ji Y, Posner MC, Roggin K, Turaga K, Chang P, Hogarth K, Siddiqui U, Gelrud A, Ha G, Freeman SS, Rhoades J, Reed S, Gydush G, Rotem D, Davison J, Imamura Y, Adalsteinnsson V, Lee J, Bass AJ, Catenacci DV: Genomic heterogeneity as a barrier to precision medicine in gastroesophageal adenocarcinoma. *Cancer Discov* 8(1):37-48, 2018.
5. Ozawa T, Kandimalla R, Gao F, Nozawa H, Hata K, Nagata H, Okada S, Izumi D, Baba H, Fleshman J, Wang X, Watanabe T, Goel A: A MicroRNA signature associated with metastasis of T1 colorectal cancers to lymph nodes. *Gastroenterology* 154(4):844-848 e7, 2018.
6. Yamada Y, Denda T, Gamoh M, Iwanaga I, Yuki S, Shimodaira H, Nakamura M, Yamaguchi T, Ohori H, Kobayashi K, Tsuda M, Kobayashi Y, Miyamoto Y, Kotake M, Shimada K, Sato A, Morita S, Takahashi S, Komatsu Y, Ishioka C: S-1 and irinotecan plus bevacizumab versus mFOLFFOX6 or CapeOX plus bevacizumab as first-line treatment in patients with metastatic colorectal cancer (TRICOLORE): a randomized, open-label, phase III, noninferiority trial. *Ann Oncol* 29(3):624-631, 2018.
7. Berger MD, Stintzing S, Heinemann V, Cao S, Yang D, Sunakawa Y, Matsusaka S, Ning Y, Okazaki S, Miyamoto Y, Suenaga M, Schirripa M, Hanna DL, Soni S, Puccini A, Zhang W, Cremolini C, Falcone A, Loupakis F, Lenz HJ: A polymorphism within the vitamin D transporter gene predicts outcome in metastatic colorectal cancer patients treated with FOLFIRI/Bevacizumab or FOLFIRI/Cetuximab. *Clin Cancer Res* 24(4):784-793, 2018.
8. Bahcall M, Awad MM, Sholl LM, Wilson FH, Xu M, Wang S, Palakurthi S, Choi J, Ivanova EV, Leonardi GC, Ulrich BC, Paweletz CP, Kirschmeier PT, Watanabe M, Baba H, Nishino M, Nagy RJ, Lanman RB, Capelletti M, Chambers ES, Redig AJ, VanderLaan PA, Costa DB, Imamura Y, Janne PA: Amplification of wild-type KRAS imparts resistance to crizotinib in MET exon 14 mutant non-small cell lung cancer. *Clin Cancer Res* 24(23):5963-5976, 2018.
9. Nakashima Y, Saeki H, Nakanishi R, Sugiyama M, Kurashige J, Oki E, Maehara Y: Assessment of sarcopenia as a predictor of poor outcomes after esophagectomy in elderly patients with esophageal cancer. *Ann Surg* 267(6):1100-1104, 2018.
10. Beppu T, Yamamoto M: Laparoscopic versus open liver resection for colorectal liver metastases-which is a more suitable standard practice? *Ann Surg* 267(2):208-209, 2018.
11. Baba Y, Yoshida N, Kinoshita K, Iwatsuki M, Yamashita Y, Chikamoto A, Watanabe M, Baba H: Clinical and prognostic features of patients with esophageal cancer and multiple primary cancers: A retrospective single-institution study. *Ann Surg* 267(3):478-483, 2018.
12. Hamada T, Zhang X, Mima K, Bullman S, Sukawa Y, Nowak JA, Kosumi K, Masugi Y, Twombly TS, Cao Y, Song M, Liu L, da Silva A, Shi Y, Gu M, Li W, Koh H, Noshio K, Inamura K, Keum N, Wu K, Meyerhardt JA, Kostic AD, Huttenhower C, Garrett WS, Meyerson M, Giovannucci EL, Chan AT, Fuchs CS, Nishihara R, Giannakis M, Ogino S: Fusobacterium nucleatum in colorectal cancer relates to immune response differentially by tumor microsatellite instability status. *Cancer Immunol Res* 6(11):1327-1336, 2018.
13. Tokunaga R, Zhang W, Naseem M, Puccini A, Berger MD, Soni S, McSkane M, Baba H, Lenz HJ: CXCL9, CXCL10, CXCL11/CXCR3 axis for immune activation - A target for novel cancer therapy. *Cancer Treat Rev* 63:40-47, 2018.
14. Liu L, Tabung FK, Zhang X, Nowak JA, Qian ZR, Hamada T, Nevo D, Bullman S, Mima K, Kosumi K, da Silva A, Song M, Cao Y, Twombly TS, Shi Y, Liu H, Gu M, Koh H, Li W, Du C, Chen Y, Li C, Li W, Mehta RS, Wu K, Wang M, Kostic AD, Giannakis M, Garrett WS, Huttenhower C, Chan AT, Fuchs CS, Nishihara R, Ogino S, Giovannucci EL: Diets that promote colon inflammation associate with risk of colorectal carcinomas that contain fusobacterium nucleatum. *Clin Gastroenterol Hepatol* 16(10):1622-1631 e3, 2018.
15. Kiyozumi Y, Iwatsuki M, Kurashige J, Ogata Y, Yamashita K, Koga Y, Toihata T, Hiyoshi Y, Ishimoto T, Baba Y, Miyamoto Y, Yoshida N, Yanagihara K, Mimori K, Baba H: PLOD2 as a potential regulator of peritoneal dissemination in gastric cancer. *Int J Cancer* 143(5):1202-1211, 2018.
16. Mizrak Kaya D, Nogueiras-Gonzales GM, Harada K, Amlashi FG, Thomas I, Rogers JE, Bhutani MS, Lee JH, Weston B, Minsky BD, Estrella JS, Blum Murphy MA, Matamoros A, Jr., Devine CE, Das P, Badgwell BD, Ajani JA: Potentially curable gastric adenocarcinoma treated without surgery. *Eur J Cancer* 98:23-29, 2018.
17. Hamada T, Liu L, Nowak JA, Mima K, Cao Y, Ng K, Twombly TS, Song M, Jung S, Dou R, Masugi Y, Kosumi K, Shi Y, da Silva A, Gu M, Li W, Keum N, Wu K, Noshio K, Inamura K, Meyerhardt JA, Nevo D, Wang M, Giannakis M, Chan AT, Giovannucci EL, Fuchs CS, Nishihara R, Zhang X, Ogino S: Vitamin D status after colorectal cancer diagnosis and patient survival according to immune response to tumour. *Eur J Cancer* 103:98-107, 2018.
18. Harada K, Pool Pizzi M, Baba H, Shanbhag ND, Song S, Ajani JA: Cancer stem cells in esophageal cancer and response to therapy. *Cancer* 124(20):3962-3964, 2018.
19. Kitano Y, Baba Y, Nakagawa S, Miyake K, Iwatsuki M, Ishimoto T, Yamashita Y, Yoshida N, Watanabe M, Nakao M, Baba H: Nrf2 promotes oesophageal cancer cell proliferation via metabolic reprogramming and detoxification of reactive oxygen species. *J Pathol* 244(3):346-357, 2018.
20. Eto T, Miyake K, Noshio K, Ohmura Y, Imamura Y, Arima K, Kanno S, Fu L, Kiyozumi Y, Izumi D, Sugihara H, Hiyoshi Y, Miyamoto Y, Sawayama H, Iwatsuki M, Baba Y, Yoshida N, Furukawa T, Araki K, Baba H, Ishimoto T: Impact of loss-of-function mutations at the RNF43 locus on colorectal cancer development and progression. *J Pathol*

- 245(4):445-455, 2018.
21. Shimodaira Y, Slack RS, Harada K, Chen HC, Sagebiel T, Bhutani MS, Lee JH, Weston B, Elimova E, Lin Q, Amlashi FG, Mizrak Kaya D, Blum MA, Roth JA, Swisher SG, Skinner HD, Hofstetter WL, Rogers JE, Mares J, Thomas I, Maru DM, Komaki R, Walsh G, Ajani JA: Influence of induction chemotherapy in trimodality therapy-eligible oesophageal cancer patients: secondary analysis of a randomised trial. *Br J Cancer* 118(3):331-337, 2018.
 22. Kitano Y, Okabe H, Yamashita Y, Nakagawa S, Saito Y, Umezaki N, Tsukamoto M, Yamao T, Yamamura K, Arima K, Kaida T, Miyata T, Mima K, Imai K, Hashimoto D, Komohara Y, Chikamoto A, Ishiko T, Baba H: Tumour-infiltrating inflammatory and immune cells in patients with extrahepatic cholangiocarcinoma. *Br J Cancer* 118(2):171-180, 2018.
 23. Hirschfield H, Bian CB, Higashi T, Nakagawa S, Zeleke TZ, Nair VD, Fuchs BC, Hoshida Y: In vitro modeling of hepatocellular carcinoma molecular subtypes for anti-cancer drug assessment. *Exp Mol Med* 50(1):e419, 2018.
 24. Hamada T, Soong TR, Masugi Y, Kosumi K, Nowak JA, da Silva A, Mu XJ, Twombly TS, Koh H, Yang J, Song M, Liu L, Gu M, Shi Y, Noshio K, Morikawa T, Inamura K, Shukla SA, Wu CJ, Garraway LA, Zhang X, Wu K, Meyerhardt JA, Chan AT, Glickman JN, Rodig SJ, Freeman GJ, Fuchs CS, Nishihara R, Giannakis M, Ogino S: TIME (Tumor Immunity in the MicroEnvironment) classification based on tumor CD274 (PD-L1) expression status and tumor-infiltrating lymphocytes in colorectal carcinomas. *Oncol Immunology* 7(7):e1442999, 2018.
 25. Satake H, Sunakawa Y, Miyamoto Y, Nakamura M, Nakayama H, Shiozawa M, Makiyama A, Kobayashi K, Kubota Y, Mori M, Kotaka M, Takagane A, Gotoh M, Takeuchi M, Fujii M, Ichikawa W, Sekikawa T: A phase II trial of 1st-line modified-FOLFOXIRI plus bevacizumab treatment for metastatic colorectal cancer harboring RAS mutation: JACCRO CC-11. *Oncotarget* 9(27):18811-18820, 2018.
 26. Miyata T, Yamashita Y, Baba Y, Harada K, Yamao T, Umezaki N, Tsukamoto M, Kitano Y, Yamamura K, Arima K, Nakagawa S, Okabe H, Imai K, Hashimoto D, Chikamoto A, Shimokawa M, Baba H: Prognostic value of LINE-1 methylation level in 321 patients with primary liver cancer including hepatocellular carcinoma and intrahepatic cholangiocarcinoma. *Oncotarget* 9(29):20795-20806, 2018.
 27. Kuroda D, Sawayama H, Kurashige J, Iwatsuki M, Eto T, Tokunaga R, Kitano Y, Yamamura K, Ouchi M, Nakamura K, Baba Y, Sakamoto Y, Yamashita Y, Yoshida N, Chikamoto A, Baba H: Controlling nutritional status (CONUT) score is a prognostic marker for gastric cancer patients after curative resection. *Gastric Cancer* 21(2):204-212, 2018.
 28. Kumagai K, Sano T, Hiki N, Nunobe S, Tsujiura M, Ida S, Ohashi M, Yamaguchi T: Survival benefit of "D2-plus" gastrectomy in gastric cancer patients with duodenal invasion. *Gastric Cancer* 21(2):296-302, 2018.
 29. Kano Y, Ohashi M, Hiki N, Takahara D, Chin K, Yamaguchi K, Tsuda Y, Shoji Y, Yasufuku I, Eto K, Ida S, Kumagai K, Nunobe S, Sano T: Favorable long-term outcomes of one-year adjuvant S-1 monotherapy for pathological stage II or III gastric cancer treated at a high-volume center. *Gastric Cancer* 21(6):1024-1030, 2018.
 30. Harada K, Dong X, Estrella JS, Correa AM, Xu Y, Hofstetter WL, Sudo K, Onodera H, Suzuki K, Suzuki A, Johnson RL, Wang Z, Song S, Ajani JA: Tumor-associated macrophage infiltration is highly associated with PD-L1 expression in gastric adenocarcinoma. *Gastric Cancer* 21(1):31-40, 2018.
 31. Eto K, Hiki N, Kumagai K, Shoji Y, Tsuda Y, Kano Y, Yasufuku I, Okumura Y, Tsujiura M, Ida S, Nunobe S, Ohashi M, Sano T, Yamaguchi T: Prophylactic effect of neoadjuvant chemotherapy in gastric cancer patients with postoperative complications. *Gastric Cancer* 21(4):703-709, 2018.
 32. Deshmukh M, Nakagawa S, Higashi T, Vincek A, Venkatesh A, Ruiz de Galarreta M, Koh AP, Goossens N, Hirschfield H, Bian CB, Fujiwara N, Ono A, Hoshida H, El-Abtah M, Ahmad NB, Lujambio A, Sanchez R, Fuchs BC, Poelstra K, Prakash J, Hoshida Y, Precision Liver Cancer Prevention C: Cell type-specific pharmacological kinase inhibition for cancer chemoprevention. *Nanomedicine* 14(2):317-325, 2018.
 33. Taniguchi H, Baba Y, Sagiya Y, Gotou M, Nakamura K, Sawada H, Yamanaka K, Sakakibara Y, Mori I, Hikichi Y, Soeda J, Baba H: Biologic response of colorectal cancer xenograft tumors to sequential treatment with panitumumab and bevacizumab. *Neoplasia* 20(7):668-677, 2018.
 34. Arima K, Komohara Y, Bu L, Tsukamoto M, Itoyama R, Miyake K, Uchihara T, Ogata Y, Nakagawa S, Okabe H, Imai K, Hashimoto D, Chikamoto A, Yamashita Y, Baba H, Ishimoto T: Downregulation of 15-hydroxyprostaglandin dehydrogenase by interleukin-1beta from activated macrophages leads to poor prognosis in pancreatic cancer. *Cancer Sci* 109(2):462-470, 2018.
 35. Kosumi K, Hamada T, Koh H, Borowsky J, Bullman S, Twombly TS, Nevo D, Masugi Y, Liu L, da Silva A, Chen Y, Du C, Gu M, Li C, Li W, Liu H, Shi Y, Mima K, Song M, Noshio K, Nowak JA, Nishihara R, Baba H, Zhang X, Wu K, Wang M, Huttenhower C, Garrett WS, Meyerson ML, Lennerz JK, Giannakis M, Chan AT, Meyerhardt JA, Fuchs CS, Ogino S: The amount of bifidobacterium genus in colorectal carcinoma tissue in relation to tumor characteristics and clinical outcome. *Am J Pathol* 188(12):2839-2852, 2018.
 36. Harada K, Wang X, Shimodaira Y, Sagebiel T, Bhutani MS, Lee JH, Weston B, Elimova E, Lin Q, Amlashi FG, Mizrak Kaya D, Lopez A, Blum Murphy MA, Roth JA, Swisher SG, Skinner HD, Hofstetter WL, Rogers JE, Thomas I, Maru DM, Komaki R, Walsh G, Ajani JA: Early metabolic change after induction chemotherapy predicts histologic response and prognosis in patients with esophageal cancer: secondary analysis of a randomized trial. *Target Oncol* 13(1):99-106, 2018.
 37. Yoshino T, Yamazaki K, Shinozaki E, Komatsu Y, Nishina T, Baba H, Tsuji A, Tsuji Y, Yamaguchi K, Sugimoto N, Denda T, Muro K, Takayama T, Esaki T, Hamamoto Y, Moriwaki T, Shimada Y, Goto M, Nakayama N, Fujii H, Tanase T, Ohtsu A: Relationship between thymidine kinase 1 expression and trifluridine/tipiracil therapy in refractory metastatic colorectal cancer: a pooled analysis of 2 randomized clinical trials. *Clin Colorectal Cancer* 17(4):e719-e732, 2018.
 38. Suenaga M, Schirripa M, Cao S, Zhang W, Yang D, Ning Y, Cremolini C, Antoniotti C, Borelli B, Mashima T, Okazaki S, Berger MD, Miyamoto Y, Gopez R, Jr., Barzi A, Lonardi S, Yamaguchi T, Falcone A, Loupakis F, Lenz HJ: Gene polymorphisms in the CCL5/CCR5 pathway as a genetic biomarker for outcome and hand-foot skin reaction in metastatic colorectal cancer patients treated with regorafenib. *Clin Colorectal Cancer* 17(2):e395-e414, 2018.
 39. Kusumoto T, Sunami E, Ota M, Yoshida K, Sakamoto Y, Tomita N, Maeda A, Mochizuki I, Okabe M, Kunieda K, Yamauchi J, Itabashi M, Kotake K, Takahashi K, Baba H, Boku N, Aiba K, Ishiguro M, Morita S, Sugihara K: Planned safety analysis of the ACTS-CC 02 trial: a randomized phase III trial of S-1 with oxaliplatin versus tegafur and uracil with leucovorin as adjuvant chemotherapy for high-risk stage III colon cancer. *Clin Colorectal Cancer* 17(2):e153-e161, 2018.
 40. Hanna DL, Loupakis F, Yang D, Cremolini C, Schirripa M, Li M, Matsusaka S, Berger MD, Miyamoto Y, Zhang W, Ning Y, Antoniotti C, Salvatore L, Moran M, Zeger G, Astrow SH, Falcone A, Lenz HJ: Prognostic value of ACVRL1 expression in metastatic colorectal cancer patients receiving first-line chemotherapy with bevacizumab: results from the triplet plus bevacizumab (TRIBE) study. *Clin Colorectal Cancer* 17(3):e471-e488, 2018.
 41. Yoshida N, Baba Y, Miyamoto Y, Iwatsuki M, Hiyoshi Y, Ishimoto T, Imamura Y, Watanabe M, Baba H: Prophylaxis of postoperative venous thromboembolism using enoxaparin after esophagectomy: a prospective observational study of effectiveness and safety. *Ann Surg Oncol* 25(8):2434-2440, 2018.
 42. Yoshida N, Baba H: ASO Author reflections: Venous thromboembolism after esophagectomy-the importance of an optimal strategy for thromboprophylaxis. *Ann Surg Oncol* 25(Suppl 3):952-953, 2018.

43. Yoshida N, Baba H: The C-reactive protein/albumin ratio may predict the long-term outcome in patients with malignant pleural mesothelioma. *Ann Surg Oncol* 25(6):1471-1472, 2018.
44. Okamura A, Watanabe M, Imamura Y, Hayami M, Yuda M, Yamashita K, Shoji Y, Mine S: Cervicoroscopic approach in esophagectomy. *Ann Surg Oncol* 25(1):333, 2018.
45. Hayami M, Hiki N, Nunobe S, Mine S, Ohashi M, Kumagai K, Ida S, Watanabe M, Sano T, Yamaguchi T: Correction to: Clinical outcomes and evaluation of laparoscopic proximal gastrectomy with double-Flap technique for early gastric cancer in the upper third of the stomach. *Ann Surg Oncol* 25(Suppl 3):990, 2018.
46. Suenaga M, Schirripa M, Cao S, Zhang W, Yang D, Cremolini C, Lonardi S, Bergamo F, Ning Y, Yamamoto N, Okazaki S, Berger MD, Miyamoto Y, Gopez R, Jr., Barzi A, Yamaguchi T, Stintzing S, Heinemann V, Loupakis F, Falcone A, Lenz HJ: Potential role of PIN1 genotypes in predicting benefit from oxaliplatin-based and irinotecan-based treatment in patients with metastatic colorectal cancer. *Pharmacogenomics J* 18(5):623-632, 2018.
47. Ning Y, Zhang W, Hanna DL, Yang D, Okazaki S, Berger MD, Miyamoto Y, Suenaga M, Schirripa M, El-Khoueiry A, Lenz HJ: Clinical relevance of EMT and stem-like gene expression in circulating tumor cells of metastatic colorectal cancer patients. *Pharmacogenomics J* 18(1):29-34, 2018.
48. Haga Y, Hato S, Ikenaga M, Yamamoto K, Tsuburaya A, Doi K, Ikejiri K, Hirata T, Yamamoto M, Ishikawa S, Takeuchi H: Validation of an assessment tool: estimation of postoperative overall survival for gastric cancer. *Eur J Surg Oncol* 44(4):515-523, 2018.
49. Yamada S, Kobayashi A, Nakamori S, Baba H, Yamamoto M, Yamaue H, Fujii T: Resection for recurrent pancreatic cancer in the remnant pancreas after pancreatectomy is clinically promising: Results of a project study for pancreatic surgery by the Japanese Society of Hepato-Biliary-Pancreatic Surgery. *Surgery* 164(5):1049-1056, 2018.
50. Shiraishi Y, Imai K, Yamashita Y, Nakao Y, Nakagawa S, Okabe H, Nitta H, Chikamoto A, Baba H: Hepatobiliary and pancreatic: segmental arterial mediolysis of pancreaticoduodenal artery accompanied by acute pancreatitis and duodenal obstruction. *J Gastroenterol Hepatol* 33(9):1564, 2018.
51. Tsukamoto M, Nitta H, Imai K, Higashi T, Nakagawa S, Okabe H, Arima K, Kaida T, Taki K, Hashimoto D, Chikamoto A, Ishiko T, Beppu T, Baba H: Clinical significance of half-lives of tumor markers alpha-fetoprotein and des-gamma-carboxy prothrombin after hepatectomy for hepatocellular carcinoma. *Hepatol Res* 48(3):E183-E193, 2018.
52. Nakagawa S, Umezaki N, Yamao T, Kaida T, Okabe H, Mima K, Imai K, Hashimoto D, Yamashita Y, Ishiko T, Chikamoto A, Baba H: Survival impact of lymphocyte infiltration into the tumor of hepatocellular carcinoma in hepatitis B virus-positive or non-B non-C patients who underwent curative resection. *Hepatol Res* 48(3):E126-E132, 2018.
53. Saeki H, Emi Y, Oki E, Tokunaga S, Kakeji Y, Akagi Y, Baba H, Baba E, Maehara Y, Kyushu Study group of Clinical C: Study protocol of a phase II clinical trial (KSCC1501A) examining oxaliplatin + S-1 for treatment of HER2-negative advanced/recurrent gastric cancer previously untreated with chemotherapy. *BMC Cancer* 18(1):57, 2018.
54. Nishikawa T, Ono K, Hashimoto S, Kinoshita H, Watanabe T, Araki H, Otsu K, Sakamoto W, Harada M, Toyonaga T, Kawakami S, Fukuda J, Haga Y, Kukidome D, Takahashi T, Araki E: One-hour oral glucose tolerance test plasma glucose at gestational diabetes diagnosis is a common predictor of the need for insulin therapy in pregnancy and postpartum impaired glucose tolerance. *J Diabetes Investig* 9(6):1370-1377, 2018.
55. Yamao T, Imai K, Yamashita Y, Kaida T, Nakagawa S, Mima K, Hashimoto D, Chikamoto A, Ishiko T, Baba H: Surgical treatment strategy for hepatocellular carcinoma in patients with impaired liver function: hepatic resection or radiofrequency ablation? *HPB (Oxford)* 20(3):244-250, 2018.
56. Nakagawa S, Okabe H, Ouchi M, Tokunaga R, Umezaki N, Higashi T, Kaida T, Arima K, Kitano Y, Kuroki H, Mima K, Nitta H, Imai K, Hashimoto D, Yamashita Y, Chikamoto A, Baba H: Enhancer of zeste homolog 2 (EZH2) regulates tumor angiogenesis and predicts recurrence and prognosis of intrahepatic cholangiocarcinoma. *HPB (Oxford)* 20(10):939-948, 2018.
57. Yamashita K, Watanabe M, Mine S, Toihata T, Fukudome I, Okamura A, Yuda M, Hayami M, Ishizuka N, Imamura Y: Minimally invasive esophagectomy attenuates the postoperative inflammatory response and improves survival compared with open esophagectomy in patients with esophageal cancer: a propensity score matched analysis. *Surg Endosc* 32(11):4443-4450, 2018.
58. Uchihara T, Yoshida N, Baba Y, Yagi T, Toihata T, Oda E, Kuroda D, Eto T, Ohuchi M, Nakamura K, Sawayama H, Kinoshita K, Iwatsuki M, Ishimoto T, Sakamoto Y, Baba H: Risk factors for pulmonary morbidities after minimally invasive esophagectomy for esophageal cancer. *Surg Endosc* 32(6):2852-2858, 2018.
59. Ohashi M, Hiki N, Ida S, Kumagai K, Nunobe S, Sano T: A novel method of intracorporeal end-to-end gastrogastrostomy in laparoscopic pylorus-preserving gastrectomy for early gastric cancer, including a unique anastomotic technique: piercing the stomach with a linear stapler. *Surg Endosc* 32(10):4337-4343, 2018.
60. Kumagai K, Hiki N, Nunobe S, Kamiya S, Tsujiura M, Ida S, Ohashi M, Yamaguchi T, Sano T: Impact of anatomical position of the pancreas on postoperative complications and drain amylase concentrations after laparoscopic distal gastrectomy for gastric cancer. *Surg Endosc* 32(9):3846-3854, 2018.
61. Kamiya S, Ohashi M, Ida S, Kumagai K, Nunobe S, Sano T, Hiki N: Laparoscopic subtotal gastrectomy with a new marking technique, endoscopic cautery marking: preservation of the stomach in patients with upper early gastric cancer. *Surg Endosc* 32(11):4681-4687, 2018.
62. Irino T, Sano T, Hiki N, Ohashi M, Nunobe S, Kumagai K, Ida S, Yamaguchi T: Diagnostic staging laparoscopy in gastric cancer: a prospective cohort at a cancer institute in Japan. *Surg Endosc* 32(1):268-275, 2018.
63. Nakagawa S, Yamashita Y, Umezaki N, Yamao T, Okabe H, Imai K, Nitta H, Hashimoto D, Chikamoto A, Baba H: Serum marker score based on prognostic nutrition index, carcinoembryonic antigen, and carbohydrate antigen 19-9 is associated with recurrence for patients undergoing surgery for pancreatic ductal adenocarcinoma. *Pancreas* 47(9):1130-1134, 2018.
64. Suyama K, Tomiguchi M, Takeshita T, Sueta A, Yamamoto-Ibusuki M, Shimokawa M, Yamamoto Y, Iwase H: Factors involved in early lenvatinib dose reduction: a retrospective analysis. *Med Oncol* 35(3):19, 2018.
65. Watanabe A, Harimoto N, Araki K, Yoshizumi T, Arima K, Yamashita Y, Baba H, Tetsuya H, Kuwano H, Shirabe K: A new strategy based on fluorodeoxyglucose-positron emission tomography for managing liver metastasis from colorectal cancer. *J Surg Oncol* 118(7):1088-1095, 2018.
66. Mizrak Kaya D, Nogueras-Gonzalez GM, Harada K, Amlashi FG, Roy-Chowdhuri S, Estrella JS, Das P, Lee JH, Weston B, Bhutani MS, Matamoros A, Jr., Thomas I, Lin Q, Badgwell BD, Ajani JA: Risk of peritoneal metastases in patients who had negative peritoneal staging and received therapy for localized gastric adenocarcinoma. *J Surg Oncol* 117(4):678-684, 2018.
67. Hayami M, Watanabe M, Ishizuka N, Mine S, Imamura Y, Okamura A, Kurogochi T, Yamashita K: Prognostic impact of postoperative pulmonary complications following salvage esophagectomy after definitive chemoradiotherapy. *J Surg Oncol* 117(6):1251-1259, 2018.
68. Sakamoto K, Honda G, Beppu T, Kotake K, Yamamoto M, Takahashi K, Endo I, Hasegawa K, Itabashi M, Hashiguchi Y, Kotera Y, Kobayashi S, Yamaguchi T, Morita S, Miyazaki M, Sugihara K, Joint Committee for Nationwide Survey on

- Colorectal Liver M: Comprehensive data of 3,820 patients newly diagnosed with colorectal liver metastasis between 2005 and 2007: report of a nationwide survey in Japan. *J Hepatobiliary Pancreat Sci* 25(2):115-123, 2018.
69. Taguchi N, Oda S, Imuta M, Yamamura S, Yokota Y, Nakaura T, Nagayama Y, Kidoh M, Utsunomiya D, Funama Y, Baba H, Yamashita Y: Dual-energy computed tomography colonography using dual-layer spectral detector computed tomography: Utility of virtual monochromatic imaging for electronic cleansing. *Eur J Radiol* 108:7-12, 2018.
 70. Masuda T, Dann AM, Elliott IA, Baba H, Kim S, Sedarat A, Muthusamy VR, Girgis MD, Joe Hines O, Reber HA, Donahue TR: A comprehensive assessment of accurate lymph node staging and preoperative detection in resected pancreatic cancer. *J Gastrointest Surg* 22(2):295-302, 2018.
 71. Hamaguchi T, Tsuji A, Yamaguchi K, Takeda K, Uetake H, Esaki T, Amagai K, Sakai D, Baba H, Kimura M, Matsumura Y, Tsukamoto T: A phase II study of NK012, a polymeric micelle formulation of SN-38, in unresectable, metastatic or recurrent colorectal cancer patients. *Cancer Chemother Pharmacol* 82(6):1021-1029, 2018.
 72. Yoshida N, Nakamura K, Kuroda D, Baba Y, Miyamoto Y, Iwatsuki M, Hiyoshi Y, Ishimoto T, Imamura Y, Watanabe M, Baba H: Preoperative smoking cessation is integral to the prevention of postoperative morbidities in minimally invasive esophagectomy. *World J Surg* 42(9):2902-2909, 2018.
 73. Schirripa M, Zhang W, Yang D, Cao S, Okazaki S, Loupakis F, Berger MD, Ning Y, Miyamoto Y, Suenaga M, Alberti G, West JD, Lonardi S, Khoukaz T, Bergamo F, Battaglin F, Antoniotti C, Falcone A, Stintzing S, Heinemann V, Lenz HJ: NOS2 polymorphisms in prediction of benefit from first-line chemotherapy in metastatic colorectal cancer patients. *PLoS One* 13(3):e0193640, 2018.
 74. Okamura A, Watanabe M, Fukudome I, Yamashita K, Yuda M, Hayami M, Imamura Y, Mine S: Relationship between visceral obesity and postoperative inflammatory response following minimally invasive esophagectomy. *World J Surg* 42(11):3651-3657, 2018.
 75. Okabe H, Yoshizumi T, Yamashita Y, Imai K, Hayashi H, Nakagawa S, Itoh S, Harimoto N, Ikegami T, Uchiyama H, Beppu T, Aishima S, Shirabe K, Baba H, Maehara Y: Histological architectural classification determines recurrence pattern and prognosis after curative hepatectomy in patients with hepatocellular carcinoma. *PLoS One* 13(9):e0203856, 2018.
 76. Miyata T, Yamashita Y, Higashi T, Taki K, Izumi D, Kosumi K, Tokunaga R, Nakagawa S, Okabe H, Imai K, Hashimoto D, Chikamoto A, Baba H: The prognostic impact of controlling nutritional status (CONUT) in Intrahepatic cholangiocarcinoma following curative hepatectomy: A retrospective single institution study. *World J Surg* 42(4):1085-1091, 2018.
 77. Kiyozumi Y, Yoshida N, Ishimoto T, Yagi T, Koga Y, Uchihara T, Sawayama H, Hiyoshi Y, Iwatsuki M, Baba Y, Miyamoto Y, Watanabe M, Matsuyama T, Oya N, Baba H: Prognostic factors of salvage esophagectomy for residual or recurrent esophageal squamous cell carcinoma after definitive chemoradiotherapy. *World J Surg* 42(9):2887-2893, 2018.
 78. Yoshida N, Baba Y, Kuroda D, Miyamoto Y, Iwatsuki M, Hiyoshi Y, Ishimoto T, Sawayama H, Imamura Y, Watanabe M, Baba H: Clinical utility of exhaled carbon monoxide in assessing preoperative smoking status and risks of postoperative morbidity after esophagectomy. *Dis Esophagus* 31(9), 2018.
 79. Kosumi K, Yoshida N, Okadome K, Eto T, Kuroda D, Ohuchi M, Kiyozumi Y, Nakamura K, Izumi D, Tokunaga R, Harada K, Mima K, Sawayama H, Ishimoto T, Iwatsuki M, Baba Y, Miyamoto Y, Watanabe M, Baba H: Minimally invasive esophagectomy may contribute to long-term respiratory function after esophagectomy for esophageal cancer. *Dis Esophagus* 31(6), 2018.
 80. Harada K, Yoshida N, Baba Y, Nakamura K, Kosumi K, Ishimoto T, Iwatsuki M, Miyamoto Y, Sakamoto Y, Ajani JA, Watanabe M, Baba H: Pyloroplasty may reduce weight loss 1 year after esophagectomy. *Dis Esophagus* 31(3), 2018.
 81. Sawayama H, Iwatsuki M, Kuroda D, Toihata T, Uchihara T, Koga Y, Yagi T, Kiyozumi Y, Eto T, Hiyoshi Y, Ishimoto T, Baba Y, Miyamoto Y, Yoshida N, Baba H: Total iron-binding capacity is a novel prognostic marker after curative gastrectomy for gastric cancer. *Int J Clin Oncol* 23(4):671-680, 2018.
 82. Miyamoto Y, Tsuji A, Tanioka H, Maekawa S, Kawanaka H, Kitazono M, Oki E, Emi Y, Murakami H, Ogata Y, Saeki H, Shimokawa M, Natsugoe S, Akagi Y, Baba H, Maehara Y: Correction to: S-1 and irinotecan plus bevacizumab as second-line chemotherapy for patients with oxaliplatin-refractory metastatic colorectal cancer: a multicenter phase II study in Japan (KSCC1102). *Int J Clin Oncol* 23(2):402, 2018.
 83. Imai K, Yamashita Y, Miyamoto Y, Nakagawa S, Okabe H, Hashimoto D, Chikamoto A, Baba H: The predictors and oncological outcomes of repeat surgery for recurrence after hepatectomy for colorectal liver metastases. *Int J Clin Oncol* 23(5):908-916, 2018.
 84. Yamashita K, Watanabe M, Mine S, Fukudome I, Okamura A, Yuda M, Hayami M, Imamura Y: The impact of the charlson comorbidity index on the prognosis of esophageal cancer patients who underwent esophagectomy with curative intent. *Surg Today* 48(6):632-639, 2018.
 85. Umezaki N, Hashimoto D, Nakagawa S, Kitano Y, Yamamura K, Chikamoto A, Matsumura F, Baba H: Number of acinar cells at the pancreatic stump predicts pancreatic fistula after pancreaticoduodenectomy. *Surg Today* 48(8):790-795, 2018.
 86. Tokunaga R, Sakamoto Y, Nakagawa S, Miyamoto Y, Yoshida N, Baba H: Additional lymph node dissection for primary colorectal cancer invading another colon region. *Surg Today* 48(7):667-672, 2018.
 87. Takeyama H, Beppu T, Higashi T, Kaida T, Arima K, Taki K, Imai K, Nitta H, Hayashi H, Nakagawa S, Okabe H, Hashimoto D, Chikamoto A, Ishiko T, Tanaka M, Sasaki Y, Baba H: Impact of surgical treatment after sorafenib therapy for advanced hepatocellular carcinoma. *Surg Today* 48(4):431-438, 2018.
 88. Sawayama H, Iwatsuki M, Kuroda D, Toihata T, Uchihara T, Koga Y, Yagi T, Kiyozumi Y, Eto T, Hiyoshi Y, Ishimoto T, Baba Y, Miyamoto Y, Yoshida N, Baba H: The association of the lymph node ratio and serum carbohydrate antigen 19-9 with early recurrence after curative gastrectomy for gastric cancer. *Surg Today* 48(11):994-1003, 2018.
 89. Sakamoto Y, Iwatsuki M, Sakata K, Toyama E, Takata N, Yoshinaka I, Harada K, Baba H: Laparoscopic omental filling with intraoperative endoscopy for a perforated duodenal ulcer. *Surg Today* 48(11):1031-1034, 2018.
 90. Nakanishi R, Oki E, Sasaki S, Hirose K, Jogo T, Edahiro K, Korehisa S, Taniguchi D, Kudo K, Kurashige J, Sugiyama M, Nakashima Y, Ohgaki K, Saeki H, Maehara Y: Sarcopenia is an independent predictor of complications after colorectal cancer surgery. *Surg Today* 48(2):151-157, 2018.
 91. Shimizu D, Saito T, Ito S, Masuda T, Kurashige J, Kuroda Y, Eguchi H, Kodera Y, Mimori K: Overexpression of FGFR1 Promotes Peritoneal Dissemination Via Epithelial-to-Mesenchymal Transition in Gastric Cancer. *Cancer Genomics Proteomics* 15(4):313-320, 2018.
 92. Lopez A, Harada K, Mizrak Kaya D, Dong X, Song S, Ajani JA: Liquid biopsies in gastrointestinal malignancies: when is the big day? *Expert Rev Anticancer Ther* 18(1):19-38, 2018.
 93. Okamura A, Watanabe M, Yamashita K, Yuda M, Hayami M, Imamura Y, Mine S: Implication of visceral obesity in patients with esophageal squamous cell carcinoma. *Langenbecks Arch Surg* 403(2):245-253, 2018.
 94. Tanioka H, Miyamoto Y, Tsuji A, Asayama M, Shiraiishi T, Yuki S, Kotaka M, Makiyama A, Shimokawa M, Shimose T, Masuda S, Yamaguchi T, Komatsu Y, Saeki H, Emi Y, Baba H, Oki E, Maehara Y, Kyushu Study Group of Clinical C:

- Prophylactic effect of dexamethasone onregorafenib-related fatigue and/or malaise: a randomized, placebo-controlled, double-blind clinical study in patients with unresectable metastatic colorectal cancer (KSCC1402/HGCSG1402). *Oncology* 94(5):289-296, 2018.
95. Amlashi FG, Wang X, Davila RE, Maru DM, Bhutani MS, Lee JH, Weston BR, Mizrak Kaya D, Vassilakopoulou M, Harada K, Blum Murphy MA, Rice DC, Hofstetter WL, Davila M, Nguyen QN, Ajani JA: Barrett's esophagus after bimodality therapy in patients with esophageal adenocarcinoma. *Oncology* 95(2):81-90, 2018.
 96. Arima K, Yamashita Y, Hashimoto D, Nakagawa S, Umezaki N, Yamao T, Tsukamoto M, Kitano Y, Yamamura K, Miyata T, Okabe H, Ishimoto T, Imai K, Chikamoto A, Baba H: Clinical usefulness of postoperative C-reactive protein/albumin ratio in pancreatic ductal adenocarcinoma. *Am J Surg* 216(1):111-115, 2018.
 97. Taguchi N, Oda S, Imuta M, Yamamura S, Nakaura T, Utsunomiya D, Kidoh M, Nagayama Y, Yuki H, Hirata K, Iyama Y, Funama Y, Baba H, Yamashita Y: Model-based iterative reconstruction in low-radiation-dose computed tomography colonography: preoperative assessment in patients with colorectal cancer. *Acad Radiol* 25(4):415-422, 2018.
 98. Hirono S, Kawai M, Okada KI, Fujii T, Sho M, Sato S, Amano R, Eguchi H, Mataka Y, Nakamura M, Matsumoto I, Baba H, Tani M, Kawabata Y, Nagakawa Y, Yamada S, Murakami Y, Shimokawa T, Yamaue H: MAPLE-PD trial (Mesenteric Approach vs. Conventional Approach for Pancreatic Cancer during Pancreaticoduodenectomy): study protocol for a multicenter randomized controlled trial of 354 patients with pancreatic ductal adenocarcinoma. *Trials* 19(1):613, 2018.
 99. Baba Y, Yagi T, Sawayama H, Hiyoshi Y, Ishimoto T, Iwatsuki M, Miyamoto Y, Yoshida N, Baba H: Long interspersed element-1 methylation level as a prognostic biomarker in gastrointestinal cancers. *Digestion* 97(1):26-30, 2018.
 100. Torzilli G, Viganò L, Cimino M, Imai K, Vibert E, Donadon M, Mansour D, Castaing D, Adam R: Is enhanced one-stage hepatectomy a safe and feasible alternative to the two-stage hepatectomy in the setting of multiple bilobar colorectal liver metastases? a comparative analysis between two pioneering centers. *Dig Surg* 35(4):323-332, 2018.
 101. Suyama K, Iwase H: Lenvatinib: a promising molecular targeted agent for multiple cancers. *Cancer Control* 25:1-5, 2018.
 102. Yoshida M, Beppu T, Shiraishi S, Tsuda N, Sakamoto F, Kuramoto K, Okabe H, Nitta H, Imai K, Tomiguchi S, Baba H, Yamashita Y: Liver function in areas of hepatic venous congestion after hepatectomy for liver cancer: (99m)Tc-GSA SPECT/CT fused imaging study. *Anticancer Res* 38(5):3089-3095, 2018.
 103. Tsukamoto M, Yamashita Y, Imai K, Umezaki N, Yamao T, Kaida T, Mima K, Nakagawa S, Hashimoto D, Chikamoto A, Ishiko T, Baba H: Long-term favorable outcomes of radiofrequency ablation for hepatocellular carcinoma as an initial treatment: a single-center experience over a 10-year period. *Anticancer Res* 38(2):1047-1052, 2018.
 104. Miyamoto Y, Oki E, Emi Y, Tokunaga S, Shimokawa M, Ogata Y, Akagi Y, Sakamoto Y, Tanaka T, Saeki H, Maehara Y, Baba H: Low visceral fat content is a negative predictive marker for bevacizumab in metastatic colorectal cancer. *Anticancer Res* 38(1):491-499, 2018.
 105. Masuda T, Margonis GA, Andreatos N, Wang J, Warner S, Mirza MB, Angelou A, Damaskos C, Garmpis N, Sasaki K, He J, Imai K, Yamashita Y, Wolfgang CL, Baba H, Weiss MJ: Combined hepatic resection and radio-frequency ablation for patients with colorectal cancer liver metastasis: a viable option for patients with a large number of tumors. *Anticancer Res* 38(11):6353-6360, 2018.
 106. Kuramoto K, Beppu T, Nitta H, Imai K, Masuda T, Miyata T, Koga Y, Kitano Y, Kaida T, Nakagawa S, Okabe H, Hayashi H, Hashimoto D, Yamashita Y, Chikamoto A, Kikuchi K, Baba H: Hepatic resection followed by hepatic arterial infusion chemotherapy for hepatocellular carcinoma with intrahepatic dissemination. *Anticancer Res* 38(1):525-531, 2018.
 107. Koga Y, Beppu T, Miyata T, Kitano Y, Tsuji A, Nakagawa S, Arima K, Kuramoto K, Okabe H, Imai K, Hayashi H, Nitta H, Yamashita Y, Chikamoto A, Ishiko T, Baba H: Predicting poorly differentiated hepatocellular carcinoma that meets the milan criteria. *Anticancer Res* 38(7):4093-4099, 2018.
 108. Kinoshita K, Beppu T, Miyata T, Kuramoto K, Yoshida Y, Umesaki N, Kitano Y, Nakagawa S, Okabe H, Nitta H, Imai K, Hayashi H, Yamashita Y, Komori H, Horino K, Misumi A, Baba H: A case of 15-year recurrence-free survival after microwave coagulation therapy for liver metastasis from gastric cancer. *Anticancer Res* 38(3):1595-1598, 2018.
 109. Imai K, Yamashita Y, Yusa T, Nakao Y, Itoyama R, Nakagawa S, Okabe H, Chikamoto A, Ishiko T, Baba H: Microvascular invasion in small-sized hepatocellular carcinoma: significance for outcomes following hepatectomy and radiofrequency ablation. *Anticancer Res* 38(2):1053-1060, 2018.
 110. Daitoku N, Miyamoto Y, Tokunaga R, Sakamoto Y, Hiyoshi Y, Iwatsuki M, Baba Y, Iwagami S, Yoshida N, Baba H: Controlling nutritional status (CONUT) score is a prognostic marker in metastatic colorectal cancer patients receiving first-line chemotherapy. *Anticancer Res* 38(8):4883-4888, 2018.
 111. Ikeda O, Inoue S, Tamura Y, Yamashita Y, Baba H, Inomata Y, Yamashita Y: Shunt-preserving disconnection of the portal to systemic circulation in patients with hepatic encephalopathy. *Acta Radiol* 59(4):441-447, 2018.
 112. Yoshida N, Baba H: Neoadjuvant chemoradiotherapy followed by surgery is associated with better survival outcomes in patients with locally advanced esophageal squamous cell carcinoma. *J Thorac Dis* 10(Suppl 26):S3067-S3068, 2018.
 113. Yoshida N, Baba H: Clinical usefulness of the surgical Apgar score for estimating short-term and prognostic outcomes after esophagectomy. *J Thorac Dis* 10(Suppl 18):S2103-S2105, 2018.
 114. Harada K, Mizrak Kaya D, Baba H, Ajani JA: Immune checkpoint blockade therapy for esophageal squamous cell carcinoma. *J Thorac Dis* 10(2):699-702, 2018.
 115. Takeya H, Shiota T, Yagi T, Ohnishi K, Baba Y, Miyasato Y, Kiyozumi Y, Yoshida N, Takeya M, Baba H, Komohara Y: High CD169 expression in lymph node macrophages predicts a favorable clinical course in patients with esophageal cancer. *Pathol Int* 68(12):685-693, 2018.
 116. Ohuchi M, Sakamoto Y, Tokunaga R, Kiyozumi Y, Nakamura K, Izumi D, Kosumi K, Harada K, Kurashige J, Iwatsuki M, Baba Y, Miyamoto Y, Yoshida N, Shono T, Naoe H, Sasaki Y, Baba H: Increased EZH2 expression during the adenoma-carcinoma sequence in colorectal cancer. *Oncol Lett* 16(4):5275-5281, 2018.
 117. Akagi J, Baba H, Sekine T, Ogawa K: Terminally differentiated CD8(+) T cells and CD57(-)FOXP3(+)/CD8(+) T cells are highly associated with the efficacy of immunotherapy using activated autologous lymphocytes. *Oncol Lett* 15(6):9529-9536, 2018.
 118. Akagi J, Baba H: CD57 ratio as a convenient and useful immunological and prognostic parameter for stage IV carcinoma. *Oncol Lett* 15(6):9257-9263, 2018.
 119. Muto J, Sugiyama M, Shirabe K, Mukaide M, Kirikae-Muto I, Ikegami T, Yoshizumi T, Yamashita Y, Maehara Y, Mizokami M: Frequency and characteristics of occult hepatitis B infection among hepatocellular carcinoma patients in Japan. *Ann Hepatol* 17(4):596-603, 2018.
 120. Allard MA, Castro-Benitez C, Imai K, Selten J, Lopez A, Sebahg M, Lemoine A, Sa Cunha A, Cherqui D, Castaing D, Vibert E, Adam R: Suitability of livers for transplantation when treated by normothermic machine perfusion. *Clin Transplant* 32(6):e13256, 2018.
 121. Okumura Y, Takamatsu M, Ohashi M, Yamamoto Y, Yamamoto N, Kawachi H, Ida S, Kumagai K, Nunobe S, Hiki N, Sano T: Gastric adenocarcinoma of fundic gland type with aggressive transformation and lymph node metastasis: a case report. *J Gastric Cancer* 18(4):409-416, 2018.

122. Ida S, Hiki N, Ishizawa T, Kuriki Y, Kamiya M, Urano Y, Nakamura T, Tsuda Y, Kano Y, Kumagai K, Nunobe S, Ohashi M, Sano T: Pancreatic compression during lymph node dissection in laparoscopic gastrectomy: possible cause of pancreatic leakage. *J Gastric Cancer* 18(2):134-141, 2018.
123. Saito T, Toya R, Yoshida N, Shono T, Matsuyama T, Ninomura S, Watakabe T, Sasaki Y, Baba H, Oya N: Spleen dose-volume parameters as a predictor of treatment-related lymphopenia during definitive chemoradiotherapy for esophageal cancer. *In Vivo* 32(6):1519-1525, 2018.
124. Yoshida N, Akiyama T, Kinoshita K, Nagai Y, Baba Y, Ishimoto T, Harada K, Tokunaga R, Kosumi K, Baba H: Percutaneous transluminal plasty: a novel approach for refractory anastomotic stricture after esophagectomy. *Esophagus* 15(4):301-303, 2018.
125. Watanabe M, Okamura A, Toihata T, Yamashita K, Yuda M, Hayami M, Fukudome I, Imamura Y, Mine S: Recent progress in perioperative management of patients undergoing esophagectomy for esophageal cancer. *Esophagus* 15(3):160-164, 2018.
126. Tanaka Y, Ueno T, Yoshida N, Akutsu Y, Takeuchi H, Baba H, Matsubara H, Kitagawa Y, Yoshida K: The effect of an elemental diet on oral mucositis of esophageal cancer patients treated with DCF chemotherapy: a multi-center prospective feasibility study (EPOC study). *Esophagus* 15(4):239-248, 2018.
127. Okamura A, Watanabe M, Fukudome I, Yamashita K, Yuda M, Hayami M, Imamura Y, Mine S: Surgical team proficiency in minimally invasive esophagectomy is related to case volume and improves patient outcomes. *Esophagus* 15(2):115-121, 2018.
128. Yamamura K, Hashimoto D, Kitano Y, Kuroda D, Eto T, Arima K, Kaida T, Miyata T, Nakagawa S, Imai K, Yamashita Y, Chikamoto A, Matsumura F, Baba H: Multiple primary cancers in patients with pancreatic cancer. *Am Surg* 84(12):e514-e516(3), 2018.
129. Beppu T, Hayashi H, Yoshida M, Nitta H, Imai K, Okabe H, Miyata T, Higashi T, Nakagawa S, Masuda T, Hashimoto D, Miyamoto Y, Chikamoto A, Ishiko T, Shiraiishi S, Yamashita Y, Baba H: Preoperative chemotherapy on functional liver regeneration for colorectal liver metastases assessed with 99mTc-GSA SPECT/CT imaging. *Int Surg* 102(9-10):431-439, 2018.
130. Yamashita Y, Imai K, Yusa T, Nakao Y, Kitano Y, Nakagawa S, Okabe H, Chikamoto A, Ishiko T, Yoshizumi T, Aishima S, Maehara Y, Baba H: Microvascular invasion of single small hepatocellular carcinoma ≤ 3 cm: Predictors and optimal treatments. *Ann Gastroenterol Surg* 2(3):197-203, 2018.
131. Yamane T, Imai K, Umezaki N, Yamao T, Kaida T, Nakagawa S, Yamashita Y, Chikamoto A, Ishiko T, Baba H: Perforation of the esophagus due to thermal injury after laparoscopic radiofrequency ablation for hepatocellular carcinoma: a case for caution. *Surg Case Rep* 4(1):127, 2018.
132. Watanabe M, Baba H: Biological basis of esophageal squamous cell carcinoma. *Modern Thoracic Oncology* 3:3-5, 2018.
133. Watanabe M: Introduction to the special issue on reviews of gastric cancer metastasis and treatment. *J Cancer Metastasis Treat* 4:48, 2018.
134. Umezaki N, Hashimoto D, Nakagawa S, Yamao T, Tsukamoto M, Kitano Y, Arima K, Yamamura K, Miyata T, Okabe H, Chikamoto A, Matsumura F, Baba H: Cystic gastric metastasis from pancreatic cancer. *Surg Case Rep* 4(1):31, 2018.
135. Uchihara T, Ishimoto T, Yonemura A, Baba H: Therapeutic targets against gastric cancer stem cells interacting with tumor microenvironment. *J Cancer Metastasis Treat* 4:9, 2018.
136. Tokunaga R, Sakamoto Y, Nakagawa S, Miyamoto Y, Yoshida N, Baba H: Para-sacral approach for large gastrointestinal stromal tumor of the lower rectum. *Int Canc Conf J* 7(2):40-42, 2018.
137. Toihata T, Imamura Y, Watanabe M, Baba H: Management of metastatic esophagogastric junction adenocarcinoma. *J Cancer Metastasis Treat* 4:24, 2018.
138. Shimizu K, Hashimoto D, Umezaki N, Nakagawa S, Yamamura K, Chikamoto A, Matsumura F, Baba H: Thoracic wall muscle metastasis from pancreatic cancer. *Surg Case Rep* 4(1):12, 2018.
139. Sawayama H, Ishimoto T, Baba H: Microenvironment in the pathogenesis of gastric cancer metastasis. *J Cancer Metastasis Treat* 4:10, 2018.
140. Sakamoto Y, Hiyoshi Y, Sakata K, Toyama E, Takata N, Yoshinaka I, Harada K, Baba H: Case of cecal volvulus successfully treated with endoscopic colopexy. *Asian J Endosc Surg* 11(4):402-404, 2018.
141. Preziosi M, Okabe H, Poddar M, Singh S, Monga SP: Endothelial Wnts regulate beta-catenin signaling in murine liver zonation and regeneration: A sequel to the Wnt-Wnt situation. *Hepatol Commun* 2(7):845-860, 2018.
142. Nakamura K, Iwatsuki M, Kurashige J, Ishimoto T, Baba Y, Miyamoto Y, Yoshida N, Watanabe M, Baba H: Circulating tumor cells in gastric cancer. *J Cancer Metastasis Treat* 4:32, 2018.
143. Nakahara O, Baba H: Phosphoglyceride crystal deposition disease in the abdominal wall: a case report. *Surg Case Rep* 4(1):120, 2018.
144. Mizrak Kaya D, Harada K, Amlashi FG, Vasilakopoulou M, Ajani JA: Customization of therapy for gastroesophageal adenocarcinoma patients. *Chronic Dis Transl Med* 4(1):8-17, 2018.
145. Miyata T, Beppu T, Kuramoto K, Nakagawa S, Imai K, Hashimoto D, Namimoto T, Yamashita Y, Chikamoto A, Yamashita Y, Baba H: Hepatic sclerosed hemangioma with special attention to diffusion-weighted magnetic resonance imaging. *Surg Case Rep* 4(1):3, 2018.
146. Lopez A, Harada K, Mizrak Kaya D, Ajani JA: Current therapeutic landscape for advanced gastroesophageal cancers. *Ann Transl Med* 6(4):78, 2018.
147. Kosumi K, Mima K, Baba H, Ogino S: Dysbiosis of the gut microbiota and colorectal cancer: the key target of molecular pathological epidemiology. *J Lab Precis Med* 2018(3):76, 2018.
148. Koga Y, Beppu T, Imai K, Kuramoto K, Miyata T, Kitano Y, Nakagawa S, Okabe H, Okabe K, Yamashita Y, Chikamoto A, Baba H: Complete remission of advanced hepatocellular carcinoma following transient chemoembolization and portal vein ligation. *Surg Case Rep* 4(1):102, 2018.
149. Kiyozumi Y, Iwatsuki M, Yamashita K, Koga Y, Yoshida N, Baba H: Update on targeted therapy and immune therapy for gastric cancer, 2018. *J Cancer Metastasis Treat* 4:31, 2018.
150. Kitamura F, Doi K, Ishiodori H, Ohchi T, Baba H: Primary extramedullary plasmacytoma of the sigmoid colon with perforation: a case report. *Surg Case Rep* 4(1):28, 2018.
151. Jogo T, Oki E, Fujiwara M, Kurashige J, Nakanishi R, Sugiyama M, Nakashima Y, Saeki H, Tsuruta S, Nishimura M, Oda Y, Maehara Y: Non-familial juvenile polyposis of the stomach with gastric cancers: a case report. *Surg Case Rep* 4(1):79, 2018.
152. Iwatsuki M, Harada K, Baba H, Ajani JA: Higher rate of colon polyp detection aided by an artificial intelligent software. *Transl Gastroenterol Hepatol* 3:106, 2018.
153. Imai K, Baba H: Liver resection for hepatocellular carcinoma associated with hepatic vein invasion: is it time to reconsider the current treatment guidelines? *Hepatobiliary Surg Nutr* 7(4):300-301, 2018.
154. Ida S, Watanabe M: Conversion surgery for stage IV gastric cancer. *J Cancer Metastasis Treat* 4:22, 2018.

155. Ida S, Hiki N: Laparoscopic-assisted total gastrectomy for esophagogastric junctional adenocarcinoma. *Ann Laparosc Endosc Surg* 2018(3):16, 2018.
156. Harada K, Song S, Ajani JA: Attenuation of YAP1 can potentially target cancer stem cells to overcome drug resistance. *Oncoscience* 5(7-8):214-215, 2018.
157. Harada K, Mizrak Kaya D, Lopez A, Baba H, Ajani JA: Personalized therapy based on image for esophageal or gastroesophageal junction adenocarcinoma. *Ann Transl Med* 6(4):80, 2018.
158. Harada K, Lopez A, Shanbhag N, Badgwell B, Baba H, Ajani JA: Recent advances in the management of gastric adenocarcinoma patients. *F1000Res* 7(F1000 Faculty Rev):1365, 2018.
159. Harada K, Baba H, Ajani JA: Recent trend in gastric cancer treatment in the USA. *J Cancer Metastasis Treat* 4:18, 2018.
160. Hamada T, Kosumi K, Nakai Y, Koike K: Surrogate study endpoints in the era of cancer immunotherapy. *Ann Transl Med* 6(Suppl 1):S27, 2018.
161. Funakoshi T, Horimatsu T, Nakamura M, Shiroshita K, Suyama K, Mukoyama M, Mizukami T, Sakurada T, Baba E, Tsuruya K, Nozaki A, Yahata K, Ozaki Y, Ubara Y, Yasui H, Yoshimoto A, Fukuma S, Kondo N, Matsubara T, Matsubara K, Fukuhara S, Yanagita M, Muto M: Chemotherapy in cancer patients undergoing haemodialysis: a nationwide study in Japan. *ESMO Open* 3(2):e000301, 2018.
162. Eto K, Ida S, Watanabe M, Baba H: Treatment strategy for metastatic gastric cancer in Japan. *J Cancer Metastasis Treat* 4:23, 2018.
163. Beppu T, Kinoshita K, Miyamoto Y, Imai K, Baba H: Is laparoscopic simultaneous resection of primary colorectal cancer and liver metastases beneficial? *Ann Laparosc Endosc Surg* 3:88, 2018.
164. Beppu T, Imai K, Kinoshita K, Yoshida Y, Baba H: Can laparoscopic liver resection for colorectal liver metastases provide early initiation of adjuvant chemotherapy? *Ann Laparosc Endosc Surg* 3:35, 2018.
165. Beppu T, Hayashi N, Miyata T, Sato N, Yoshida Y: Is laparoscopic liver resection for hepatocellular carcinoma in patients with well-preserved liver cirrhosis superior to conventional open liver resection? *Laparoscopic Surgery* 2:64, 2018.
166. Baba Y, Baba H: Gene-expression signature may be useful for the prediction of lymph node metastasis in esophageal cancer. *Ann Transl Med* 6(11):230, 2018.
167. Baba H: Editorial. *Ann Gastroenterol Surg* 2(1):4-5, 2018.
168. Li F, Xu Y, Liu B, Singh PK, Zhao W, Jin J, Han G, Scott AW, Dong X, Huo L, Ma L, Pizzi MP, Wang Y, Li Y, Harada K, Xie M, Skinner HD, Ding S, Wang L, Krishnan S, Johnson RL, Song S, Ajani JA: YAP1-Mediated CDK6 Activation Confers Radiation Resistance in Esophageal Cancer - Rationale for the combination of YAP1 and CDK4/6 inhibitors in esophageal cancer. *Clin Cancer Res* (Doi: 10.1158/1078-0432.CCR-18-1029), 2018.
169. Yoshida N, Kosumi K, Tokunaga R, Baba Y, Nagai Y, Miyamoto Y, Iwagami S, Iwatsuki M, Hiyoshi Y, Ishimoto T, Eto K, Imamura Y, Watanabe M, Baba H: Clinical importance of mean corpuscular volume as a prognostic marker after esophagectomy for esophageal cancer: a retrospective study. *Ann Surg* (Doi: 10.1097/SLA.0000000000002971), 2018.
170. Okadome K, Baba Y, Yagi T, Kiyozumi Y, Ishimoto T, Iwatsuki M, Miyamoto Y, Yoshida N, Watanabe M, Baba H: Prognostic Nutritional Index, Tumor-infiltrating Lymphocytes, and Prognosis in Patients with Esophageal Cancer. *Ann Surg* (Doi: 10.1097/SLA.0000000000002985), 2018.
171. Kiyozumi Y, Baba Y, Okadome K, Yagi T, Ishimoto T, Iwatsuki M, Miyamoto Y, Yoshida N, Watanabe M, Komohara Y, Baba H: IDO1 Expression Is Associated With Immune Tolerance and Poor Prognosis in Patients With Surgically Resected Esophageal Cancer. *Ann Surg* (Doi: 10.1097/SLA.0000000000002754), 2018.
172. Kim DS, Kim BW, Hatano E, Hwang S, Hasegawa K, Kudo A, Ariizumi S, Kaibori M, Fukumoto T, Baba H, Kim SH, Kubo S, Kim JM, Ahn KS, Choi SB, Jeong CY, Shima Y, Nagano H, Yamasaki O, Yu HC, Han DH, Seo HI, Park IY, Yang KS, Yamamoto M, Wang HJ: Surgical Outcomes of Hepatocellular Carcinoma With Bile Duct Tumor Thrombus: A Korea-Japan Multicenter Study. *Ann Surg* (Doi: 10.1097/SLA.0000000000003014), 2018.
173. Hidaka M, Eguchi S, Okuda K, Beppu T, Shirabe K, Kondo K, Takami Y, Ohta M, Shiraishi M, Ueno S, Nanashima A, Noritomi T, Kitahara K, Fujioka H: Impact of anatomical resection for hepatocellular carcinoma with microportal invasion (vp1): a multi-institutional study by the kyushu study group of liver surgery. *Ann Surg* (Doi: 10.1097/SLA.0000000000002981), 2018.
174. Hashimoto D, Arima K, Nakagawa S, Negoro Y, Hirata T, Hirota M, Inomata M, Fukuzawa K, Ohga T, Saeki H, Oki E, Yamashita Y, Chikamoto A, Baba H, Maehara Y: Pancreatic cancer arising from the remnant pancreas after pancreatectomy: a multicenter retrospective study by the Kyushu Study Group of Clinical Cancer. *J Gastroenterol* (Doi: 10.1007/s00535-018-01535-9), 2018.
175. Imai K, Yamashita Y, Miyamoto Y, Nakao Y, Yusa T, Itoyama R, Nakagawa S, Okabe H, Hiyoshi Y, Nitta H, Chikamoto A, Baba H: Implication of primary tumor location for the indication of preoperative chemotherapy in patients with colorectal liver metastases. *HPB (Oxford)* (Doi: 10.1016/j.hpb.2018.08.012), 2018.
176. Kumai Y, Miyamoto T, Matsubara K, Samejima Y, Yoshida N, Baba H, Orita Y: Determining the Efficacy of the Chin-Down Maneuver Following Esophagectomy With Fiberoptic Endoscopic Evaluation of Swallowing. *Arch Phys Med Rehabil* (Doi: 10.1016/j.apmr.2018.10.007), 2018.
177. Nakao Y, Sakamoto Y, Miyamoto Y, Kurashige J, Imamura Y, Hiyoshi Y, Ida S, Iwagami S, Baba Y, Yoshida N, Baba H: Laparoscopic resection of a subclinical functioning para-aortic paraganglioma. *Int Surg* (Doi: 10.9738/intsurg-d-16-00115.1), 2018.
178. Harada K, Abdelhakeem AAF, Ajani JA: A balancing act: dual immune-checkpoint inhibition for oesophagogastric cancer. *Nat Rev Clin Oncol* 16(1):9-10, 2019.
179. Russell JO, Lu WY, Okabe H, Abrams M, Oertel M, Poddar M, Singh S, Forbes SJ, Monga SP: Hepatocyte-specific beta-catenin deletion during severe liver injury provokes cholangiocytes to differentiate into hepatocytes. *Hepatology* 69(2):742-759, 2019.
180. Hamada T, Nowak JA, Masugi Y, Drew DA, Song M, Cao Y, Kosumi K, Mima K, Twombly TS, Liu L, Shi Y, da Silva A, Gu M, Li W, Noshio K, Keum N, Giannakis M, Meyerhardt JA, Wu K, Wang M, Chan AT, Giovannucci EL, Fuchs CS, Nishihara R, Zhang X, Ogino S: Smoking and risk of colorectal cancer sub-classified by tumor-infiltrating T cells. *J Natl Cancer Inst* 111(1):42-51, 2019.
181. Yagi T, Baba Y, Ishimoto T, Iwatsuki M, Miyamoto Y, Yoshida N, Watanabe M, Baba H: PD-L1 expression, tumor-infiltrating lymphocytes, and clinical outcome in patients with surgically resected esophageal cancer. *Ann Surg* 269(3):471-478, 2019.
182. Imai K, Benitez CC, Allard MA, Vibert E, Cunha AS, Cherqui D, Castaing D, Bismuth H, Baba H, Adam R: Impact of surgical treatment for recurrence after 2-stage hepatectomy for colorectal liver metastases, on patient outcome. *Ann Surg* 269(2):322-330, 2019.
183. Tokunaga R, Naseem M, Lo JH, Battaglin F, Soni S, Puccini A, Berger MD, Zhang W, Baba H, Lenz HJ: B cell and B cell-related pathways for novel cancer treatments. *Cancer Treat Rev* 73:10-19, 2019.
184. Yagi T, Baba Y, Okadome K, Kiyozumi Y, Hiyoshi Y, Ishimoto T, Iwatsuki M, Miyamoto Y, Yoshida N, Watanabe M,

- Komohara Y, Baba H: Tumour-associated macrophages are associated with poor prognosis and programmed death ligand 1 expression in oesophageal cancer. *Eur J Cancer* 111:38-49, 2019.
185. Kosumi K, Hamada T, Zhang S, Liu L, da Silva A, Koh H, Twombly TS, Mima K, Morikawa T, Song M, Nowak JA, Nishihara R, Saltz LB, Niedzwiecki D, Ou FS, Zemla T, Mayer RJ, Baba H, Ng K, Giannakis M, Zhang X, Wu K, Giovannucci EL, Chan AT, Fuchs CS, Meyerhardt JA, Ogino S: Prognostic association of PTGS2 (COX-2) over-expression according to BRAF mutation status in colorectal cancer: Results from two prospective cohorts and CALGB 89803 (Alliance) trial. *Eur J Cancer* 111:82-93, 2019.
 186. Arima K, Ohmuraya M, Miyake K, Koiwa M, Uchiyama T, Izumi D, Gao F, Yonemura A, Bu L, Okabe H, Imai K, Hashimoto D, Baba Y, Chikamoto A, Yamashita Y, Furukawa T, Araki K, Baba H, Ishimoto T: Inhibition of 15-PGDH causes Kras-driven tumor expansion through prostaglandin E2-ALDH1 signaling in the pancreas. *Oncogene* 38(8):1211-1224, 2019.
 187. Izumi D, Gao F, Toden S, Sonohara F, Kanda M, Ishimoto T, Kodera Y, Wang X, Baba H, Goel A: A genomewide transcriptomic approach identifies a novel gene expression signature for the detection of lymph node metastasis in patients with early stage gastric cancer. *EBioMedicine* 41:268-275, 2019.
 188. Liu Y, Baba Y, Ishimoto T, Iwatsuki M, Hiyoshi Y, Miyamoto Y, Yoshida N, Wu R, Baba H: Progress in characterizing the linkage between Fusobacterium nucleatum and gastrointestinal cancer. *J Gastroenterol* 54(1):33-41, 2019.
 189. Iwatsuki M, Yamamoto H, Miyata H, Kakeji Y, Yoshida K, Konno H, Seto Y, Baba H: Effect of hospital and surgeon volume on postoperative outcomes after distal gastrectomy for gastric cancer based on data from 145,523 Japanese patients collected from a nationwide web-based data entry system. *Gastric Cancer* 22(1):190-201, 2019.
 190. Lopez A, Harada K, Vasilakopoulou M, Shanbhag N, Ajani JA: Targeting angiogenesis in colorectal carcinoma. *Drugs* 79(1):63-74, 2019.
 191. Tsukamoto M, Imai K, Ishimoto T, Komohara Y, Yamashita Y, Nakagawa S, Umezaki N, Yamao T, Kitano Y, Miyata T, Arima K, Okabe H, Baba Y, Chikamoto A, Ishiko T, Hirota M, Baba H: PD-L1 expression enhancement by infiltrating macrophage-derived tumor necrosis factor-alpha leads to poor pancreatic cancer prognosis. *Cancer Sci* 110(1):310-320, 2019.
 192. Giganti F, Tang L, Baba H: Gastric cancer and imaging biomarkers: Part 1 - a critical review of DW-MRI and CE-MDCT findings. *Eur Radiol* 29(4):1743-1753, 2019.
 193. Imai K, Yamashita Y, Nakao Y, Uemura N, Kitamura F, Miyata T, Nakagawa S, Okabe H, Hayashi H, Chikamoto A, Ishiko T, Baba H: Is disease progression a contraindication for the strategy of portal vein embolization followed by hepatectomy for hepatocellular carcinoma? *Surgery* 165(4):696-702, 2019.
 194. Yamashita Y, Imai K, Kaida T, Yamao T, Tsukamoto M, Nakagawa S, Okabe H, Chikamoto A, Ishiko T, Yoshizumi T, Ikeda T, Maehara Y, Baba H: Multimodal radiofrequency ablation versus laparoscopic hepatic resection for the treatment of primary hepatocellular carcinoma within Milan criteria in severely cirrhotic patients: long-term favorable outcomes over 10 years. *Surg Endosc* 33(1):46-51, 2019.
 195. Akagi J, Baba H: Hydrogen gas restores exhausted CD8+ T cells in patients with advanced colorectal cancer to improve prognosis. *Oncol Rep* 41(1):301-311, 2019.
 196. Miyake K, Baba Y, Ishimoto T, Hiyoshi Y, Iwatsuki M, Miyamoto Y, Yoshida N, Watanabe M, Ogata Y, Nagayama M, Silsirivanit A, Kobayashi D, Araki N, Baba H: Isocitrate dehydrogenase gene mutations and 2-hydroxyglutarate accumulation in esophageal squamous cell carcinoma. *Med Oncol* 36(1):11, 2019.
 197. Tokunaga R, Nakagawa S, Miyamoto Y, Ohuchi M, Izumi D, Kosumi K, Taki K, Higashi T, Miyata T, Yoshida N, Baba H: The impact of preoperative anaemia and anaemic subtype on patient outcome in colorectal cancer. *Colorectal Dis* 21(1):100-109, 2019.
 198. Hiyoshi Y, Miyamoto Y, Kato R, Sawayama H, Eto K, Nagai Y, Iwagami S, Baba Y, Yoshida N, Baba H: Laparoscopic sigmoidectomy and double-stapling technique anastomosis via needlescopic surgery - a video vignette. *Colorectal Dis* 21(1):122-123, 2019.
 199. Nakao Y, Okabe H, Yamashita Y, Itoyama R, Yusa T, Kitano Y, Arima K, Miyata T, Nakagawa S, Imai K, Chikamoto A, Baba H: A case of acute perforated cholecystitis with intracystic tumor thrombus of hepatocellular carcinoma. *Int J Clin Oncol* 8(1):43-45, 2019.
 200. Hiyoshi Y, Miyamoto Y, Kiyozumi Y, Sawayama H, Eto K, Nagai Y, Iwatsuki M, Iwagami S, Baba Y, Yoshida N, Kawanaka K, Yamashita Y, Baba H: CT-guided percutaneous radiofrequency ablation for lung metastases from colorectal cancer. *Int J Clin Oncol* 24(3):288-295, 2019.
 201. Matsumoto T, Okabe H, Yamashita Y, Yusa T, Itoyama R, Nakao Y, Yamao T, Umzaki N, Tsukamoto M, Kitano Y, Miyata T, Arima K, Nitta H, Hayashi H, Imai K, Chikamoto A, Baba H: Clinical role of fludeoxyglucose (18F) positron emission tomography/computed tomography ((18)F-FDG PET/CT) in patients with pancreatic neuroendocrine tumors. *Surg Today* 49(1):21-26, 2019.
 202. Kuroguchi T, Honda M, Yamashita K, Hayami M, Okamura A, Imamura Y, Mine S, Watanabe M: Safety and efficacy of preoperative chemotherapy followed by esophagectomy versus upfront surgery for resectable esophageal squamous cell carcinoma. *Surg Today* 49(2):150-157, 2019.
 203. Kurahara H, Shinchi H, Ohtsuka T, Miyasaka Y, Matsunaga T, Noshiro H, Adachi T, Eguchi S, Imamura N, Nanashima A, Sakamoto K, Nagano H, Ohta M, Inomata M, Chikamoto A, Baba H, Watanabe Y, Nishihara K, Yasunaga M, Okuda K, Natsugoe S, Nakamura M: Significance of neoadjuvant therapy for borderline resectable pancreatic cancer: a multicenter retrospective study. *Langenbecks Arch Surg* 404(2):167-174, 2019.
 204. Okabe H, Ohsaki T, Ogawa K, Ozaki N, Hayashi H, Akahoshi S, Ikuta Y, Ogata K, Baba H, Takamori H: Frailty predicts severe postoperative complications after elective colorectal surgery. *Am J Surg* 217(4):677-681, 2019.
 205. Miyamoto Y, Hiyoshi Y, Akiyama T, Kiyozumi Y, Eto K, Yohei N, Iwagami S, Baba Y, Yoshida N, Baba H: Low skeletal muscle mass before salvage-line chemotherapy is a poor prognostic factor in patients with refractory metastatic colorectal cancer. *Digestion* 99(1):79-85, 2019.
 206. Imamura Y, Watanabe M, Toihata T, Takamatsu M, Kawachi H, Haraguchi I, Ogata Y, Yoshida N, Saeki H, Oki E, Taguchi K, Yamamoto M, Morita M, Mine S, Hiki N, Baba H, Sano T: Recent incidence trend of surgically resected esophagogastric junction adenocarcinoma and microsatellite instability status in Japanese patients. *Digestion* 99(1):6-13, 2019.
 207. Yamao T, Yamashita Y, Imai K, Umezaki N, Tsukamoto M, Kitano Y, Arima K, Miyata T, Nakagawa S, Okabe H, Hayashi H, Chikamoto A, Ishiko T, Baba H: Clinical significance of preoperative hepatocellular carcinoma with high lens culinaris agglutinin-reactive fraction of alpha-fetoprotein, but low alpha-fetoprotein. *Anticancer Res* 39(2):883-889, 2019.
 208. Umezaki N, Hashimoto D, Yamashita Y, Nakagawa S, Nakao Y, Itoyama R, Yusa T, Yamao T, Okabe H, Imai K, Hayashi H, Chikamoto A, Baba H: Neuroendocrine tumor of the hilar bile duct. *Anticancer Res* 39(2):903-907, 2019.
 209. Nomoto D, Yoshida N, Akiyama T, Kiyozumi Y, Eto K, Hiyoshi Y, Nagai Y, Iwatsuki M, Iwagami S, Baba Y, Miyamoto Y, Baba H: Influence of neoadjuvant chemotherapy on short-term outcomes after minimally invasive esophagectomy for

- esophageal cancer. *Anticancer Res* 39(1):471-475, 2019.
210. Hashimoto D, Okawa T, Maruyama R, Matsumura F, Shibata Y, Kohrogi H: Anticoagulant therapy for disseminated intravascular coagulation after gastrointestinal surgery. *Anticancer Res* 39(1):25-31, 2019.
211. Arima K, Nitta H, Beppu T, Nakagawa S, Okabe H, Imai K, Chikamoto A, Yamashita Y, Yamashita Y, Baba H: Impact of Repeated Hepatectomy on Liver Regeneration in Hepatocellular Carcinoma: A Propensity Score-based Analysis. *Anticancer Res* 39(2):965-970, 2019.
212. Yoshida N, Baba H: Risk factors for chylothorax after esophagectomy. *J Thorac Dis* 11(S3):S196-S197, 2019.
213. Kurashige J, Yokobori T, Mima K, Sawada G, Takahashi Y, Ueo H, Takano Y, Matsumura T, Uchi R, Eguchi H, Sudo T, Sugimachi K, Mori M, Baba H, Mimori K: Plastin3 is associated with epithelial-mesenchymal transition and poor prognosis in gastric cancer. *Oncol Lett* 17(2):2393-2399, 2019.
214. Yamashita Y, Imai K, Nakagawa S, Nakao Y, Yusa T, Itoyama R, Okabe H, Hayashi H, Chikamoto A, Baba H: Ultrasonography-guided suction thrombectomy for an isolated portal vein thrombus in liver surgery. *In Vivo* 33(1):209-212, 2019.
215. Hara Y, Miyamoto Y, Hiyoshi Y, Iwatsuki M, Baba Y, Yoshida N, Baba H: Severe Encephalopathy, Lactic Acidosis and Hyperammonaemia With FOLFIRI Plus Aflibercept After Two-stage Hepatectomy: A Case Report. *In Vivo* 33(2):563-565, 2019.
216. Mima K, Baba H: The gut microbiome, antitumor immunity, and liver cancer. *HepatoBiliary Surg Nutr* 8(1):67-68, 2019.
217. Iwatsuki M, Harada K, Iwagami S, Eto K, Ishimoto T, Baba Y, Yoshida N, Ajani JA, Baba H: Neoadjuvant and adjuvant therapy for gastrointestinal stromal tumors. *Ann Gastroenterol Surg* 3(1):43-49, 2019.
218. Itoyama R, Yamashita Y, Nakao Y, Yusa T, Umezaki N, Yamao T, Nakagawa S, Okabe H, Imai K, Hayashi H, Hashimoto D, Chikamoto A, Baba H: Carcinosarcoma of Vater's papilla: case report of a rare neoplasm and review of the literature. *Surg Case Rep* 5(1):13, 2019.
219. Harada M, Takahashi T, Haga Y, Nishikawa T: Comparative study on quick sequential organ failure assessment, systemic inflammatory response syndrome and the shock index in prehospital emergency patients: single-site retrospective study. *Acute Med Surg* 6(2):131-137, 2019.
220. Adam R, Kitano Y: Multidisciplinary approach of liver metastases from colorectal cancer. *Ann Gastroenterol Surg* 3(1):50-56, 2019.
221. Tokunaga R, Xiu J, Johnston C, Goldberg RM, Philip PA, Seeber A, Naseem M, Lo JH, Arai H, Battaglin F, Puccini A, Berger MD, Soni S, Zhang W, Hwang JJ, Shields AF, Marshall JL, Baba H, Korn WM, Lenz HJ: Molecular profiling of appendiceal adenocarcinoma and comparison with right-sided and left-sided colorectal cancer. *Clin Cancer Res* (Doi: 10.1158/1078-0432.CCR-18-3388), 2019.
222. Yoshida N, Yamamoto H, Baba H, Miyata H, Watanabe M, Toh Y, Matsubara H, Kakeji Y, Seto Y: Can Minimally Invasive Esophagectomy Replace Open Esophagectomy for Esophageal Cancer? Latest Analysis of 24,233 Esophagectomies From the Japanese National Clinical Database. *Ann Surg* (Doi: 10.1097/SLA.0000000000003222), 2019.
223. Harada K, Wu CC, Wang X, Mizrak Kaya D, Amlashi FG, Iwatsuki M, Blum Murphy MA, Maru DM, Weston B, Lee JH, Rogers JE, Thomas I, Shanbhag N, Bhutani MS, Hofstetter WL, Nguyen QN, Ajani JA: Total Lesion Glycolysis Assessment Identifies a Patient Fraction With a High Cure Rate Among Esophageal Adenocarcinoma Patients Treated With Definitive Chemoradiation. *Ann Surg* (Doi: 10.1097/SLA.0000000000003228), 2019.
224. Bu L, Baba H, Yoshida N, Miyake K, Yasuda T, Uchihara T, Tan P, Ishimoto T: Biological heterogeneity and versatility of cancer-associated fibroblasts in the tumor microenvironment. *Oncogene* (Doi: 10.1038/s41388-019-0765-y), 2019.
225. Shoji Y, Kumagai K, Kamiya S, Ida S, Nunobe S, Ohashi M, Yoshimizu S, Horiuchi Y, Yoshio T, Ishiyama A, Hirasawa T, Osako T, Yamamoto N, Fujisaki J, Sano T, Hiki N: Prospective feasibility study for single-tracer sentinel node mapping by ICG (indocyanine green) fluorescence and OSNA (one-step nucleic acid amplification) assay in laparoscopic gastric cancer surgery. *Gastric Cancer* (Doi: 10.1007/s10120-018-00919-3), 2019.
226. Koga Y, Iwatsuki M, Yamashita K, Kiyozumi Y, Kurashige J, Masuda T, Eto K, Iwagami S, Harada K, Ishimoto T, Baba Y, Yoshida N, Miyazaki N, Takamori H, Ajani JA, Baba H: The role of FBXW7, a cell-cycle regulator, as a predictive marker of recurrence of gastrointestinal stromal tumors. *Gastric Cancer* (Doi: 10.1007/s10120-019-00950-y), 2019.
227. Umezaki N, Nakagawa S, Yamashita Y, Kitano Y, Arima K, Miyata T, Hiyoshi Y, Okabe H, Nitta H, Hayashi H, Imai K, Chikamoto A, Baba H: Lysyl oxidase induces epithelial-mesenchymal transition and predict intrahepatic metastasis of hepatocellular carcinoma. *Cancer Sci* (Doi: 10.1111/cas.14010), 2019.
228. Sawayama H, Ogata Y, Ishimoto T, Mima K, Hiyoshi Y, Iwatsuki M, Baba Y, Miyamoto Y, Yoshida N, Baba H: Glucose transporter 1 regulates the proliferation and cisplatin sensitivity of esophageal cancer. *Cancer Sci* (Doi: 10.1111/cas.13995), 2019.
229. Yoshida N, Nagai Y, Baba Y, Miyamoto Y, Iwagami S, Iwatsuki M, Hiyoshi Y, Eto K, Ishimoto T, Kiyozumi Y, Nomoto D, Akiyama T, Imamura Y, Watanabe M, Baba H: Effect of Resection of the Thoracic Duct and Surrounding Lymph Nodes on Short- and Long-Term and Nutritional Outcomes After Esophagectomy for Esophageal Cancer. *Ann Surg Oncol* (Doi: 10.1245/s10434-019-07304-z), 2019.
230. Yamao T, Yamashita Y, Yamamura K, Nakao Y, Tsukamoto M, Nakagawa S, Okabe H, Hayashi H, Imai K, Baba H: Cellular Senescence, Represented by Expression of Caveolin-1, in Cancer-Associated Fibroblasts Promotes Tumor Invasion in Pancreatic Cancer. *Ann Surg Oncol* (Doi: 10.1245/s10434-019-07266-2), 2019.
231. Yamashita K, Iwatsuki M, Koga Y, Toihata T, Kiyozumi Y, Kuroda D, Eto K, Hiyoshi Y, Iwagami S, Baba Y, Miyamoto Y, Yoshida N, Baba H: Preservation of physiological passage through the remnant stomach prevents postoperative malnutrition after proximal gastrectomy with double tract reconstruction. *Surg Today* (Doi: 10.1007/s00595-019-01799-5), 2019.
232. Ishikawa S, Sawayama H, Matsuo A, Uchino R, Honda S, Hirota M, Baba H: Construction and validation of a simple scoring system for stage III colorectal cancer recurrence (SiS-SCORE). A case control study. *Jpn J Clin Oncol* (Doi: 10.1093/jjco/hyy192), 2019.
233. Kitano Y, Yamashita Y, Nakagawa S, Okabe H, Imai K, Chikamoto A, Baba H: Effectiveness of surgery for recurrent cholangiocarcinoma: A single center experience and brief literature review. *Am J Surg* (Doi: 10.1016/j.amjsurg.2019.02.015), 2019.
234. Kinoshita S, Yamashita K, Iwatsuki M, Sato H, Matsumoto C, Matsumoto T, Shiraiishi Y, Yoshida N, Baba H: Disseminated carcinomatosis of the bone marrow from gastric cancer during pregnancy. *Clin J Gastroenterol* (Doi: 10.1007/s12328-019-00963-1), 2019.
235. Akiyama T, Miyamoto Y, Nomoto D, Kiyozumi Y, Eto K, Hiyoshi Y, Iwatsuki M, Nagai Y, Iwagami S, Baba Y, Yoshida N, Baba H: Laparoscopic dissection for pelvic lymph node recurrence of thymic carcinoma: A case report. *Asian J Endosc Surg* (Doi: 10.1111/ases.12688), 2019.
236. Shimura T, Toden S, Kandimalla R, Toiyama Y, Okugawa Y, Kanda M, Baba H, Kodera Y, Kusunoki M, Goel A: A

- genomewide expression profiling results in identification of a novel miRNA-based signature for the detection of peritoneal metastasis in patients with gastric cancer *Ann Surg* (in press)
237. Kosumi K, Baba Y, Okadome K, Yagi T, Kiyozumi Y, Yoshida N, Watanabe M, Baba H: Tumor Long-interspersed Nucleotide Element-1 Methylation Level and Immune Response to Esophageal Cancer. *Ann Surg* (in press)
238. Goel A, Izumi D, Toden S, Ureta E, Ishimoto T, Baba H: TIAM1 promotes chemoresistance and tumor invasiveness in colorectal cancer. *Cell Death Dis* (in press)
239. Miyamoto Y, Hiyoshi Y, Daitoku N, Okadome K, Sakamoto Y, Yamashita K, Kuroda D, Sawayama H, Iwatsuki M, Baba Y, Yoshida N, Baba H: Naples prognostic score is a useful prognostic marker in patients with metastatic colorectal cancer. *Dis Colon Rectum* (in press)
240. Ozaki K, Hayashi H, Ikuta Y, Masuda T, Akaboshi S, Ogata K, Matumoto K, Ogawa K, Kamio T, Baba H, Takamori H: Conversion surgery for initially unresectable pancreatic ductal adenocarcinoma with synchronous liver metastasis after treatment with FOLFIRINOX – A case report. *Clin J Gastroenterol* (in press)

呼吸器外科学講座

【研究プロジェクト名および概要】

- I. 肺癌における DNA 異常メチル化の解析
 - . 胸部腫瘍に対する腫瘍内圧測定の意義
 - . 肺腺癌の発生にかかわる遺伝的素因の研究
- IV. 肺腺癌の発生、進行とエストロゲン代謝の関連の解析
- V. 呼吸器外科手術前後の低酸素血症の定量的評価

【教職員および大学院学生】

教授 鈴木 実
准教授 池田 公英
講師 白石 健治
助教 増田 佳子
助教 藤野 孝介

大学院生 山田 竜也
大学院生 大隅 祥暢
大学院生 新地 祐介
大学院生 松原 恵理
大学院生 眞田 宗
医員 田中 秀和
医員 山田 紘之
医員 濱崎 博一

技術補佐員 吉田 彩香
事務補佐員 重藤 尚子

【メールアドレス】

smakoto@kumamoto-u.ac.jp
koei@cg7.so-net.ne.jp

【研究プロジェクト】

研究の統括
I, III, IV
I, III,
I, III, IV

【連絡先】 電話: 096-373-5533 Fax: 096-373-5532

【ホームページ】 <http://kumadai-thoraic.com/>

【特殊技術・特殊装置】

1. 腫瘍内圧測定

【英文論文】

1. Novel approach to pleurodesis with 50 % glucose for air leakage after lung resection or pneumothorax.
Fujino K.*, Motooka Y., Koga T., Osumi H., Matsubara E., Shibata H., Ikeda K., Shiraishi K., Mori T., Hayashi K., Yoshimoto K., Wakimoto J., Kubota I., Suzuki M.
Surg Today 46, 599-602 (2016) [IF, 1.329; citation, 3]
2. Synchronous Multiple Lung Adenocarcinomas: Estrogen Concentration in Peripheral Lung.
Ikeda K.*, Shiraishi K., Yoshida A., Shinchi Y., Sanada M., Motooka Y., Fujino K., Mori T., Suzuki M.
PLoS One. 11 (2016) [IF, 3.057; citation, 0]
3. Chronic Progressive Pulmonary Aspergillosis after Surgery for Lung Cancer
Yamada T, Mori T, Nishi W, Motooka Y, Ikeda K, Shiraishi K, Suzuki M.
Kyobu Geka.2016Sep;69(10) Japanese.PubMed PMID:27586316.

4. Insulinoma-Associated Protein 1 Is a Crucial Regulator of Neuroendocrine Differentiation in Lung Cancer.
Fujino K, Motooka Y, Hassan WA, Ali Abdalla MO, Sato Y, Kudoh S, Hasegawa K, Niimori-Kita K, Kobayashi H, Kubota I, Wakimoto J, Suzuki M, Ito T
Am J Pathol. 2015 Dec;185(12):3164-77.
5. Interstitial Fluid Pressure Correlates Clinicopathological Factors of Lung Cancer.
Mori T, Koga T, Shibata H, Ikeda K, Shiraishi K, Suzuki M, Iyama KI.
Ann Thorac Cardiovasc Surg. 2015 Jan 26
6. Metastasectomy of Pulmonary Metastases from Osteosarcoma: Prognostic Factors and Indication for Repeat Metastasectomy
Matsubara E, Mori T, Koga T, Shibata H, Ikeda K, Shiraishi K, Suzuki M
Respir Med 2015
7. Prognostic Significance of Aberrant Methylation of Solute Carrier Gene Family 5A8 in Lung Adenocarcinoma.
Ikeda K.*, Shiraishi K., Koga T., Motooka Y., Fujino K., Shibata H., Mori T., Suzuki M
Ann Thorac Surg. 99, 1755-1759 (2015) [IF, 3.021; citation, 2]

【和文論文】

1. 左肺癌術直後の肺静脈断端内血栓による塞栓症の2例
古賀教将 森毅 柴田英克 池田公英 白石健治 鈴木実
日本呼吸器外科学会 30 巻 5 号 (2016)
2. ProGRP 高値を示した非定型肺カルチノイドの1例
山田竜也 吉本健太郎
日本臨床外科学会誌第 77 巻 6 号 (2016)

心臓血管外科学講座

【研究プロジェクト名および概要】

- 動脈硬化進展、動脈瘤形成に関する基礎的ならびに臨床的研究
 - 1. 動脈硬化の発症・進展における分子機構の解析
 - 2. 動脈瘤発生における分子機構の解析
- 虚血性心疾患の外科治療に関する臨床研究
 - 1. びまん性冠動脈病変に対する外科的治療
 - 2. 急性冠症候群に対する冠動脈バイパス術に関する多施設共同研究
- 日本の人工弁置換術後における抗血小板療法の有効性および安全性に関する研究
- 高齢者大動脈弁狭窄症に対する経カテーテル大動脈弁置換術と外科的大動脈弁置換術の臨床的研究
- 動脈瘤に対するステントグラフトを用いた低侵襲手術の研究
 - 1. 胸部大動脈瘤に対するステントグラフトを用いた血管内治療 (TEVAR)
 - 2. 腹部大動脈瘤に対するステントグラフトを用いた血管内治療 (EVAR)
- 新規組織工学を用いた、心臓血管外科領域の次世代型再生医療技術開発

【教職員および大学院生】

| | | メールアドレス |
|-------|-------|--------------------------------------|
| 教授 | 福井 寿啓 | (tmfukui@kumamoto-u.ac.jp) |
| 講師 | 岡本 健 | (okaken1967cmk@kuh.kumamoto-u.ac.jp) |
| 助教 | 田爪 宏和 | (tazume@kumamoto-u.ac.jp) |
| 助教 | 野口 亮 | (ryonoguchi0812@kumamoto-u.ac.jp) |
| 特任助教 | 佐々 利明 | |
| 非常勤講師 | 高橋 幸宏 | |
| 非常勤講師 | 森山 周二 | |
| 非常勤講師 | 鈴木 龍介 | |
| 技術補佐員 | 谷口 裕子 | |
| 事務補佐員 | 船津 靖子 | (shinzou@kumamoto-u.ac.jp) |

【連絡先】 TEL:096-373-5205 FAX:096-373-5207 E-mail: shinzou@kumamoto-u.ac.jp

【ホームページ】 <http://kumamoto-cvs.com/>

【英文原著】

- Nishigawa K, Fukui T, Yamazaki M, Takanashi S. Ten-year experience of coronary endarterectomy for the diffusely diseased left anterior descending artery. *Ann Thorac Surg.* 2017;103:710-716.
- Sassa T, Okamoto K, Tazume H, Noguchi R, Koga A, Fukui T. Tricuspid valve repair with artificial chorda after previous ventricular septal repair. *Ann Thorac Surg.* 2017;103:e335-337.
- Okamoto K, Tazume H, Koga A, Fukui T. Repair of left ventricular rupture in a patient with mitral annular calcification. *Interact Cardiovasc Thorac Surg.* 2017;24:972-973.
- Usuku H, Kojima S, Kuyama N, Hanatani S, Araki S, Tshujita K, Tsunoda R, Fukui T, Hokimoto S. Multiple giant coronary artery aneurysms. *Intern Med.* 2017;56:1973-1976.
- Nakanishi N, Ishii M, Kaikita K, Okamoto K, Izumiya Y, Yamamoto E, Takashio S, Hokimoto S, Fukui T, Tsujita K. When is the optimal timing of surgical intervention for severe functional tricuspid regurgitation? Case Report in *Cardiology.* 2017;2017:9232658.
- Tazume H, Okamoto K, Fukui T. Concomitant aorto-right subclavian artery bypass with off-pump coronary artery bypass grafting: a case report. *J Cardiothorac Surg.* 2017.12:90.
- Nishida H, Tabata M, Fukui T, Sato Y, Kin H, Takanashi S. A systematic approach to improve the outcomes of type A aortic dissection. *J Thorac Cardiovasc Surg.* 2017;154:89-96.
- Nishigawa K, Fukui T, Takanashi S. Preoperative SYNTAX score to assess the late outcomes after coronary endarterectomy for the diffusely diseased left anterior descending artery. *Interact Cardiovasc Thorac Surg.* 2017;25:780-784
- Kidoh M, Utsunomiya D, Funama Y, Ashikaga H, Nakaura T, Oda S, Yuki H, Hirata K, Iyama Y, Nagayama Y, Fukui T, Yamashita Y, Taguchi K. Vectors through a cross-sectional image (VCI): A visualization method for four-dimensional motion analysis for cardiac computed tomography. *J Cardiovasc Comput Tomogr.* 2017;11:468-473.
- Fukui T. Management of acute aortic dissection and thoracic aortic rupture. *J Intensive Care.* 2017 (in press)
- Koga A, Okamoto K, Tazume H, Fukui T. On-X prosthetic valve in a 42-year old female with antiphospholipid syndrome. *Heart Surg Forum.* 2017 (in press)
- Nishida H, Fukui T, Kasegawa H, Kin H, Yamazaki M, Takanashi S. Causes of repair failure for degenerative mitral valve disease and reoperation outcomes. *Eur J Cardiothorac Surg.* 2018 (in press)

【和文総説】

- 岡本健, 福井寿啓. 内臓動脈瘤. 日本臨床増刊号. 動脈・静脈の疾患 (下) 2017;75(Suppl5):811-814.
- 福井寿啓. 冠動脈バイパス術の進歩. *Medicina.* 2017;54:1872-1875.

脳神経外科学講座

【研究プロジェクト名および概要】

I. 脳腫瘍の病態と治療に関する研究

1. 悪性グリオーマの病態解析と新規治療法の開発
2. 悪性グリオーマ以外の悪性脳腫瘍（中枢神経原発悪性リンパ腫、髄芽腫、AT/RT など）の分子生物学的特性の解明と新規治療法の開発
3. 熊本県における脳腫瘍の疫学

II. 脳血管障害疾患の病態と治療に関する研究

1. 脳卒中（脳虚血や脳出血）における神経細胞死のメカニズムとその治療法の開発
2. 血管内治療における塞栓物質とその治療法の開発
3. 脳血管障害の疫学

III. 大脳基底核疾患の病態の解明と治療に関する研究

1. 大脳基底核神経回路網形成機構の解明
2. 脳深部刺激装置を用いた大脳基底核疾患の治療

IV. 視床下部・脳下垂体疾患の病態と治療に関する研究

1. 機能性下垂体腺腫におけるホルモン産生メカニズムの解明と治療法の開発
2. 嚢胞性疾患における嚢胞形成機序の解明と根治的治療法の開発
3. 間脳・下垂体部腫瘍の疫学

V. てんかん脳の病態・機能解析

【教職員および大学院学生】

教授 武笠 晃丈
特任教授 山田 和慶
准教授 牧野 敬史
講師 浜崎 禎
講師 篠島 直樹
助教 大森 雄樹
助教 黒田 順一郎
助教 大田 和貴
助教 竹崎 達也
助教 賀来 泰之

【メールアドレス】

(mukasa@kumamoto-u.ac.jp)
(yamadakazu@kuh.kumamoto-u.ac.jp)
(kmakino@kuh.kumamoto-u.ac.jp)
(thamasaki-nsu@umin.ac.jp)
(nshinojima@kuh.kumamoto-u.ac.jp)
(ohmori4497@gmail.com)
(jukuroda@kumamoto-u.ac.jp)
(kazuohata@kuh.kumamoto-u.ac.jp)
(ttakezaki@mac.com)
(kakuyasuyuki@yahoo.co.jp)

【研究プロジェクト】

研究統括
III
I
III, V
I, IV
II
I
I
I
II

| | | | |
|------|--------|------------|----|
| 大学院生 | 賀来 藍子 | (博士課程 4 年) | I |
| 大学院生 | 岳元 裕臣 | (博士課程 4 年) | II |
| 大学院生 | 林 建佑 | (博士課程 4 年) | II |
| 大学院生 | 甲斐 恵太郎 | (博士課程 2 年) | I |
| 大学院生 | 内川 裕貴 | (博士課程 2 年) | II |
| 大学院生 | 伊東山 剛 | (博士課程 1 年) | I |
| 大学院生 | 亀野 功揮 | (博士課程 1 年) | II |

【連絡先】 Tel: 096-373-5219 Fax: 096-371-8064

【ホームページ】 <https://kumadai-neurosurgery.com/>

【特殊技術・特殊装置】

1. 細胞培養
クリーンベンチ、CO2 インキュベーターなど
2. 神経細胞初代培養
3. 脳組織スライス器官培養
4. 遺伝子工学機器
DNA-sequencer, DNA-thermal cycler, PCR など
5. 位相差顕微鏡、共焦点レーザー顕微鏡
6. 組織解析法全般
一般染色、免疫染色、蛍光染色
7. 動物実験機器
脳血流計、定位脳手術装置、血圧計、血管撮影装置、麻酔装置など
8. 生化学研究機器
遠心機、恒温槽、Western Blot 用機器など
9. 手術用ナビゲーション装置
10. 定位脳手術装置
11. 神経電気生理記録装置
12. 手術用内視鏡装置
紫色半導体レーザー装置（術中蛍光診断装置）

【英文原著】

1. Takemoto Y, Kawano T, Ohmori Y, Nakagawa T, Ohta K, Kuroda J, Yano S, Mukasa A: Dural arteriovenous fistula associated with intratumor hemorrhage. *Journal of Clinical Neuroscience* 2019, 59: 352-355,
2. Hamasaki T, Morioka M, Fujiwara K, Nakayama C, Harada M, Sakata K, Hasegawa Y, Yamakawa T, Yamada K, Mukasa A: Is hemifacial spasm affected by changes in the heart rate? A study using heart rate variability analysis, Clinical neurophysiology. *International Federation of Clinical Neurophysiology* 2018, 129:2205-2214
3. Hide T, Komohara Y, Miyasato Y, Nakamura H, Makino K, Takeya M, Kuratsu JI, Mukasa A, Yano S: Oligodendrocyte Progenitor Cells and Macrophages/Microglia Produce Glioma Stem Cell Niches at the Tumor Border. *EBioMedicine* 2018, 30:94-104
4. Imaoka Y, Kawano T, Hashiguchi A, Fujimoto K, Yamamoto K, Nishi T, Otsuka T, Yano S, Mukasa A: Modified frailty index predicts postoperative outcomes of spontaneous intracerebral hemorrhage. *Clinical Neurology and Neurosurgery*. 2018, 175:137-143
5. Inoue H, Shinojima N, Ueda R, Yamamoto K, Ishii N, Igata M, Kawashima J, Araki E, Iwase H, Mikami Y, Yano S, Mukasa A: A Rare Case of Thyrotropin-Secreting Pituitary Adenoma Coexisting with Papillary Thyroid Carcinoma Presenting with Visual Disturbance without Hyperthyroidism. *World Neurosurgery* 2018, 119:394-399
6. Makino K, Nakamura H, Shinojima N, Kuroda JI, Yano S, Mikami Y, Mukasa A: BCL2 expression is associated with a poor prognosis independent of cellular origin in primary central nervous system diffuse large B-cell lymphoma. *Journal of Neuro-oncology* 2018, 140:115-121
7. Miki S, Imamichi S, Fujimori H, Tomiyama A, Fujimoto K, Satomi K, Matsushita Y, Matsuzaki S, Takahashi M, Ishikawa E, Yamamoto T, Matsumura A, Mukasa A, Nishikawa R, Masutomi K, Narita Y, Masutani M, Ichimura K: Concomitant administration of radiation with eribulin improves the survival of mice harboring intracerebral glioblastoma. *Cancer Science* 2018, 109:2275-2285
8. Mizutani H, Nakane S, Ikeda T, Nakamura H, Takamatsu K, Makino K, Tawara N, Mukaino A, Watari M, Matsui H, Mukasa A, Ando Y: CSF TACI and BAFF levels in patients with primary CNS lymphoma as novel diagnostic biomarkers. *Annals of Clinical and Translational Neurology* 2018, 5:1611-1616
9. Nakagawa M, Nakaura T, Namimoto T, Kitajima M, Uetani H, Tateishi M, Oda S, Utsunomiya D, Makino K, Nakamura H, Mukasa A, Hirai T, Yamashita Y: Machine learning based on multi-parametric magnetic resonance imaging to differentiate glioblastoma multiforme from primary cerebral nervous system lymphoma. *European Journal of Radiology* 2018, 108:147-154
10. Ohkura A, Negoto T, Aoki T, Noguchi K, Okamoto Y, Komatani H, Kawano T, Mukasa A, Morioka M: Stenotic changes of the posterior cerebral artery are a major contributing factor for cerebral infarction in moyamoya disease. *Surgical Neurology International* 2018, 9:105
11. Otani R, Uzuka T, Higuchi F, Matsuda H, Nomura M, Tanaka S, Mukasa A, Ichimura K, Kim P, Ueki K: IDH-mutated astrocytomas with 19q-loss constitute a subgroup that confers better prognosis. *Cancer Science* 2018, 109:2327-2335
12. Shinojima N, Fujimoto K, Makino K, Todaka K, Yamada K, Mikami Y, Oda K, Nakamura K, Jono H, Kuratsu JI, Nakamura H, Yano S, Mukasa A: Clinical significance of polyglutamylation in primary central nervous system

lymphoma. *Acta neuropathologica communications* 2018, 6:15

13. Yano S, Shinojima N, Kitajima M, Uetani H, Hide T, Mukasa A: Usefulness of Oblique Coronal Computed Tomography and Magnetic Resonance Imaging in the Endoscopic Endonasal Approach to Treat Skull Base Lesions. *World Neurosurgery* 2018, 113:e10-e19
14. Imaoka Y, Ohmori Y, Fujimoto K, Kuratsu J, Yano S: Ruptured dermoid cyst consisting of two adjacent masses with different components in the middle and posterior cranial fossa. *Interdisciplinary Neurosurgery* 2018, 11: 44-46
15. Hamasaki T, Yano S, Nakamura K, Yamada K: Pregabalin as a salvage preoperative treatment for refractory trigeminal neuralgia. *Journal of Clinical Neuroscience* 2018, 47: 240-244
16. Yamamoto T, Hamasaki T, Nakamura H, Yamada K: Improvement of visual field defects after focal resection for occipital lobe epilepsy: case report. *Journal of Neurosurgery* 2018, 128(3): 862-866
17. Thomas JG, Parker Kerrigan BC, Hossain A, Gumin J, Shinojima N, Nwajei F, Ezhilarasan R, Love P, Sulman EP, Lang FF: Ionizing radiation augments glioma tropism of mesenchymal stem cells. *Journal of Neurosurgery* 2018, 128: 287-295
18. Hayashi K, Ohmori Y, Kaku Y, Takemoto Y, Nakagawa T, Yano S, Mukasa A: Non-sinus-type Dural Arteriovenous Fistula Cured by Transarterial Embolization from Middle Meningeal Artery: Two Case Reports. *Journal of Neuroendovascular Therapy*. *Journal of Neuroendovascular Therapy* 2018, 12: 542-545
19. Fishman PS, Elias WJ, Ghanouni P, Gwinn R, Lipsman N, Schwartz M, Chang JW, Taira T, Krishna V, Rezaei A, Yamada K, Igase K, Cosgrove R, Kashima H, Kaplitt MG, Tierney TS, Eisenberg HM: Neurological adverse event profile of magnetic resonance imaging-guided focused ultrasound thalamotomy for essential tremor. *Movement Disorders* 2018, 33(5): 843-847

【和文総説】

1. 武笠 晃丈:
神経膠腫の不均一性による治療抵抗性とその治療戦略 がん不均一性を理解し治療抵抗性に挑む
実験医学 2018年増刊号 36(2):307-313, 2018
2. 武笠 晃丈:
脳腫瘍のゲノム診療に向けて
Clinical Neuroscience 36(5):539-542, 2018
3. 武笠 晃丈 (日本脳神経外科学会、日本病理学会 分担執筆) 金原出版:
治療効果の判定方法
脳腫瘍取扱い規約 第4版 22-33, 2018

産科婦人科学講座

【研究プロジェクト名および概要】

I. 臨床研究

A) 生殖内分泌学

- 遅発思春期女性に対する低用量エストロゲン補充療法の効果に関する研究
- 体外受精・胚移植の成功率向上目的の臨床的研究
- 生殖医療・がん診療連携センター開設後のがん・生殖医療の検討
- 子宮内膜症の組織発生に関する形態学的解析
- 子宮内膜症治療における既存アレルギー性疾患用薬（トラニラスト）の臨床投与研究
- 原発性卵巣不全患者における減数分裂関連転写因子異常の探索

B) 産科・周産期医学

- 環境省「子どもの健康と環境に関する全国調査」(エコチル調査)
- 妊婦における歯周病評価基準の策定
- 生体肝移植ドナー女性の妊娠出産
- 子宮頸部円錐切除後の妊娠・分娩転帰についての検討

C) 婦人科腫瘍病態学

子宮頸癌

1. 予後改善を目的とした基靱帯血管群の処理を先行させる広汎子宮全摘出術の検討
2. 子宮頸部胃型粘液性癌に関する臨床病理学的検討
3. 子宮頸癌 IB2 期-IIIB 期の子宮頸部通常型腺癌における術前化学療法の有効性についての後方視的検討 (JGOG1072 試験)
4. 子宮頸癌術後再発高リスクに対する強度変調放射線治療 (IMRT) を用いた術後同時化学放射線療法の実施共同非ランダム化検証的試験 (JCOG1402 試験)

子宮体癌

1. 子宮体癌の発生とプロラクチンに関する臨床病理学的検討
2. 内分泌学的因子を包含した新たな子宮内膜癌の分類と新規治療戦略の確立
3. 若年性子宮体癌症例に対する妊孕能温存治療とその限界に関する臨床研究
4. リンパ節転移リスクを有する子宮体癌に対する傍大動脈リンパ節郭清の治療的意義に関するランダム化第 III 相試験 (JCOG1412 試験)
5. 子宮体癌再発高危険群に対する術後化学療法に関する臨床研究 (JGOG2043 試験)

卵巣癌

1. 長期経過後に再発した卵巣癌の臨床病理学および分子生物学的検討
2. プラチナ抵抗性再発卵巣癌における化学療法に関する臨床研究
3. ステージング手術が行われた上皮性卵巣癌 I 期における補助化学療法の必要性に関するランダム化第 III 相比較試験 (JGOG3020 試験)
4. 上皮性卵巣癌の妊孕性温存治療の対象拡大のための非ランダム化検証的試験 (JCOG1203 試験)
5. BRCA1/2 遺伝子バリエーションとがん発症・臨床病理学的特徴および発症リスク因子を明らかにするための卵巣がん未発症例を対象としたバイオバンク・コホート研究 (JGOG3024 試験)
6. 卵巣癌における相同組換え修復異常の頻度とその臨床的意義を明らかにする前向き観察研究 (JGOG3025 試験)
7. 再発卵巣癌における新規化学療法に関する臨床研究 (治験)

絨毛性疾患

1. 熊本県における絨毛性疾患の地域登録 (1974 年開始)

D) 婦人科腫瘍内分泌学

- 若年女性の婦人科腫瘍による卵巣摘除後の骨密度の追跡調査
- タモキシフェン治療乳癌女性の子宮内膜の変化に関する前方視的解析

II. 基礎研究

A) 周産期研究室

間葉性異形成胎盤(PMD)の臨床的・分子遺伝学的基盤研究
 糖尿病の影響を受けた胎児における膵臓特異的遺伝子発現に関する研究
 ヒト子宮奇形発生に関わる遺伝的要因の研究
 減数分裂における染色体分配の制御機構の解明(臨床-基礎連携プロジェクト)

B) 生殖内分泌研究室

生殖細胞・体細胞の相互作用に関する分子生物学的解析
 卵巣機能不全の分子生物学的解析
 チョコレート嚢胞の悪性化に関する分子生物学的解析
 未受精卵凍結融解に関する基礎的研究
 子宮内膜症の鉄・ヘモグロビン代謝におけるマクロファージの機能解析

C) 腫瘍内分泌研究室

プロラクチンを介した子宮内膜癌発癌・増殖機構の解明
 Pole 遺伝子変異を有する子宮内膜癌の発癌機序に関する検討
 内分泌学的因子を包含した新たな子宮内膜癌の分類の検討

D) 分子腫瘍研究室

新規分子標的治療をめざした卵巣癌幹細胞の研究
 Wnt/PCP の活性調節に基づいた上皮性卵巣がんの新たな治療戦略の確立(臨床-基礎連携プロジェクト)
 卵巣類内膜腺癌における ARID1A のシグナル伝達経路に関する研究
 卵巣癌の大網転移と腫瘍微小環境に関する研究
 CSF-1 および CSF-1 受容体を介した卵巣癌の進展機構に関する研究

E) 臨床形態研究室

卵巣癌細胞における Onionin A の STAT3 活性に及ぼす作用についての研究
 ヒト卵巣癌細胞株に対するサイトカインによる増殖抑制効果に関する研究
 プロゲステロンレセプター発現組織特異的 Mob1A/B ノックアウトマウスの解析
 インターフェロン 産生骨髄系 iPS 細胞を用いた進行卵巣癌の新規治療に向けた基礎的検討
 卵巣癌の発癌機序における外因性化学物質曝露の影響についての検討

| 【研究者および大学院生】 | | 【メールアドレス】 | 【研究プロジェクト】 |
|--------------|--------|------------------------------|------------|
| 教授 | 片渕 秀隆 | buchi@kumamoto-u.ac.jp | 総括 |
| 教授 | 田代 浩徳 | htashiro@kumamoto-u.ac.jp | I, II |
| 准教授 | 大場 隆 | tkohba@kumamoto-u.ac.jp | 総括 |
| 講師 | 本田 律生 | ritz@kumamoto-u.ac.jp | I, II |
| | 本原 剛志 | motorhurry2013@yahoo.co.jp | I, II |
| 助教 | 山口 宗影 | munekage@hotmail.co.jp | I, II |
| | 齋藤 文誉 | usawbunchan@yahoo.co.jp | I, II |
| | 松尾 勇二 | matsuoyuji0904@hotmail.com | I, II |
| | 値賀 正彦 | chigauchiga@yahoo.co.jp | I, II |
| | 山本 直 | aosugirusora70@yahoo.co.jp | I, II |
| | 坪木 純子 | amethyst_j_0229@yahoo.co.jp | I, II |
| 診療助手 | 竹下 優子 | ponponrunrun1129@yahoo.co.jp | I, II |
| 医員 | 柴崎 聡 | | I, II |
| | 瀬尾 優太郎 | | I, II |
| | 中村 美和 | | I, II |
| | 岸本 かおり | | I, II |
| | 下川 理沙 | | I, II |
| | 相良 昭仁 | | I, II |
| | 富永 茉莉子 | | I, II |
| | 吉村 早織 | | I, II |
| | 杉野 麗花 | | I, II |

| | | | |
|------|--|--|--|
| | 吉積 貴子 田浦 裕三子 | | I, II I, II |
| 大学院生 | 小寺 千聡 本岡 大社 マンズール・マヒナ 楠木 楨 岩越 裕 李 晨妍 中村 美和 | | I, II II II II II II I, II |

【連絡先】 Tel: 096-373-5269

【発表論文】

I. 主な英文雑誌論文 (10 編)

1. Yoneda M, Imamura R, Nitta H, Taniguchi K, Saito F, Kikuchi K, Ogi H, Tanaka T, Katabuchi H, Nakayama H, Imamura T. Enhancement of cancer invasion and growth via the C5a-C5a receptor system: Implications for cancer promotion by autoimmune diseases and association with cervical cancer invasion. *Oncol Lett* 2019; 17: 913-920
2. Motooka Y, Motohara T, Honda R, Tashiro H, Mikami Y, Katabuchi H. Radical resection of an endometrioid carcinoma arising from endometriosis in the round ligament within the right canal of Nuck: a case report and literature review. *Gynecol Oncol Rep.* 2018; 24: 61-64
3. Erdenebaatar C, Yamaguchi M, Monsur M, Saito F, Honda R, Tashiro H, Ohba T, Katabuchi H. Administration of Cabergoline Contributes to Preserving Fertility in Young Hyperprolactinemic Patients With Endometrial Cancer Treated With Medroxyprogesterone Acetate. *Int J Gynecol Cancer* 2018; 28: 539-544
4. Ishikawa M, Kasamatsu T, Tsuda H, Fukunaga M, Sakamoto A, Kaku T, Nakanishi T, Hasumi Y, Iwata T, Baba T, Nogawa T, Kudaka W, Kaneda H, Ono S, Saito F, Taniguchi Y, Okada S, Mizuno M, Onda T, Yaegashi N. Prognostic factors and optimal therapy for stages I-II neuroendocrine carcinomas of the uterine cervix: A multi-center retrospective study. *Gynecol Oncol* 2018; 148: 139-146
5. Hayata T, Chiga M, Ezura Y, Asashima M, Katabuchi H, Nishinakamura R, Noda M. Dullard deficiency causes hemorrhage in the adult ovarian follicles. *Genes Cells* 2018; 23: 345-356
6. Saito T, Tabata T, Ikushima H, Yanai H, Tashiro H, Niikura H, Minaguchi T, Muramatsu T, Baba T, Yamagami W, Ariyoshi K, Ushijima K, Mikami M, Nagase S, Kaneuchi M, Yaegashi N, Udagawa Y, Katabuchi H. Japan Society of Gynecologic Oncology guidelines 2015 for the treatment of vulvar cancer and vaginal cancer. *Int J Clin Oncol* 2018; 23: 201-234
7. Kodera C, Ohba T, Hashimoto T, Yamaguchi M, Yoshimatsu H, Katabuchi H. Sac-Type Congenital Diaphragmatic Hernia: A Case Report of Two Siblings. *Case Rep Obstet Gynecol* 2018; 3270526
8. Mikami M, Ikeda M, Sato H, Iwase H, Enomoto T, Kobayashi Y, Katabuchi H. The use of conization to identify and treat severe lesions among prediagnosed CIN1 and 2 patients in Japan. *J Gynecol Oncol* 2018; 29: e29
9. Mikami M, Shida M, Shibata T, Katabuchi H, Kigawa J, Aoki D, Yaegashi N. Impact of institutional accreditation by the Japan Society of Gynecologic Oncology on the treatment and survival of women with cervical cancer. *J Gynecol Oncol* 2018; 29: e23
10. Kondo T, Nakamura M, Kitano S, Kawashima J, Matsumura T, Ohba T, Yamaguchi M, Katabuchi H, Araki E. The clinical course and pathophysiological investigation of adolescent gestational diabetes insipidus: a case report. *BMC Endocr Disord* 2018; 18:4

II. 主な和文著書 (5 編)

1. 三上幹男、永瀬 智、宇田川康博、八重樫伸生、片瀨秀隆 (編集). **子宮体がん治療ガイドライン 2018 年版** 日本婦人科腫瘍学会 金原出版 2018
2. 片瀨秀隆. **子宮内膜増殖症 今日の治療指針 2018** 山口 徹、北原光夫監修、福井次矢、高木 誠、小室一成総編集 医学書院 1312-1313, 2018
3. 片瀨秀隆、本田律生、「難治性稀少部位子宮内膜症の集学的治療のための分類・診断・治療ガイドライン作成」研究班. **腸管子宮内膜症 稀少部位子宮内膜症診療ガイドライン** 診断と治療社 35-38, 2018
4. 値賀正彦、大場 隆. **非典型溶血性尿毒症症候群 実践臨床生殖免疫学** 柴原浩章編 中外医学社 657-659, 2018
5. 本原剛志、片瀨秀隆. **腫瘍免疫 実践よくわかる 臨床生殖免疫学入門** 柴原浩章編 中外出版社 23-32, 2018

泌尿器科学講座

【研究プロジェクト名および概要】

- I. 腎細胞癌に対する分子標的療法の感受性および抵抗性に関する研究
- II. 転座型腎細胞癌の発生・進展に関わる分子機構に関する研究
- III. 泌尿器科悪性腫瘍の発生・進展におけるマクロファージの役割に関する研究
- IV. 泌尿器科悪性腫瘍におけるアナフィラトキシン C5a とそのレセプターシステムに関する研究
- V. 3D 培養を用いた泌尿器科悪性腫瘍における新規標的分子探索に関する研究
- VI. 癌微小環境で免疫抑制に係る分子機構の解明に関する研究
- VII. 泌尿器疾患に対する治療成績に関するアウトカム研究
- VIII. 泌尿器科疾患に対する鏡視下手術・ロボット手術に関する研究
- IX. 尿路平滑筋機能および排尿機能、病態に関する研究

| | 【教職員および大学院学生】 | 【メールアドレス】 | 【研究プロジェクト】 |
|-------|---------------|------------------------|------------------------|
| 教授 | 神波 大己 | kamba@kumamoto-u.ac.jp | 研究の統括 |
| 病院講師 | 山口 隆大 | | VII, VIII |
| 助 教 | 杉山 豊 | | VI, VIII, IX |
| 助 教 | 矢津田 旬二 | | III, IV, VII, VIII |
| 助 教 | 村上 洋嗣 | | III, IV, VII, VIII |
| 助 教 | 元島 崇信 | | I, II, III, V, VI, VII |
| 助 教 | 福島 結美 | | VII, VIII, IX |
| 特任助教 | 福島 結美 | | VII, VIII, IX |
| 医 員 | 倉橋 竜磨 | | I, II, III, V, VI, VII |
| 大学院生 | 今村 隆二 | | III, IV |
| 大学院生 | 上園 英太 | | II, V, VI |
| 大学院生 | 原 千瑛 | | I, II, VI |
| 事務補佐員 | 坂田 朋美 | | |
| 事務補佐員 | 吉見 有加 | | |

【連絡先】 電話: 096-373-5241 Fax: 096-373-5242

【ホームページ】 <https://kumamoto-urology.com>

【英文論文, 著書】

1. Arakaki R, Yamasaki T, Kanno T, Shibasaki N, Sakamoto H, Utsunomiya N, Sumiyoshi T, Shibuya S, Tsuruyama T, Nakamura E, Ogawa O, Kamba T. CCL2 as a potential therapeutic target for clear cell renal cell carcinoma. **Cancer Med.** 5(10), 2920-2923, 2016
2. Kamba T, Kamoto T, Maruo S, Kikuchi T, Shimizu Y, Namiki S, Fujimoto K, Kawanishi H, Sato F, Narita S, Satoh T, Saito H, Sugimoto M, Teishima J, Masumori N, Egawa S, Sakai H, Okada Y, Terachi T, Ogawa O; ZAPCA Study Group. A phase III multicenter, randomized, controlled study of combined androgen blockade with versus without zoledronic acid in prostate cancer patients with metastatic bone disease: results of the ZAPCA trial. **Int J Clin Oncol.** 22(1), 166-173, 2017
3. Yano H, Motoshima T, Ma C, Pan C, Yamada S, Nakayama T, Kitada S, Fujimoto N, Kamba T, Takeya M, Komohara Y; The significance of TIMD4 expression in clear cell renal cell carcinoma. **Med Mol Morphol.** 50(4), 220-226, 2017
4. Motoshima T, Miura Y, Wakagami N, Kusada N, Takano T, Inoshita N, Okaneya T, Sugiyama Y, Kamba T, Takeya M, Komohara Y; Phenotypical change of tumor-associated macrophages in metastatic lesions of clear cell renal cell carcinoma. **Med Mol Morphol.** 51(1), 57-63, 2018
5. Takizawa A, Kawai K, Kawahara T, Kojima T, Maruyama S, Shinohara N, Akamatsu S, Kamba T, Nakamura T, Ukimura O, Jikuya R, Kishida T, Kakimoto K, Nishimura K, Harabayashi T, Nagamori S, Yamashita S, Arai Y, Sawada Y, Sekido N, Kinoshita H, Matsuda T, Nakagawa T, Homma Y, Nishiyama H; The usefulness of testosterone administration in identifying false-positive elevation of serum human chorionic gonadotropin in patients with germ cell tumor. **J Cancer Res Clin Oncol.** 144(1), 109-115, 2018
6. Tsuruta M, Ueda S, Yew PY, Fukuda I, Yoshimura S, Kishi H, Hamana H, Yatsuda J, Irie A, Senju S, Yuba E, Kamba T, Eto M, Nakayama H, Nishimura Y; Bladder cancer-associated cancer-testis antigen-derived long peptides encompassing both CTL and promiscuous HLA class II-restricted Th cell epitopes induced CD4+ T cells expressing converged T-cell receptor genes in vitro. **OncoImmunology.** 7(4), e1415687, 2018
7. Asano T, Ohnishi K, Shiota T, Motoshima T, Sugiyama Y, Yatsuda J, Kamba T, Ishizaka K, Komohara Y; CD169-positive sinus macrophages in the lymph nodes determine bladder cancer prognosis. **Cancer Sci.** 109(5), 1723-1730, 2018
8. Sakamoto H, Yamasaki T, Sumiyoshi T, Utsunomiya N, Takeda M, Kamba T, Nakamura E, Ogawa O; A family case with germline TSC1 and mtDNA mutations developing bilateral eosinophilic chromophobe renal cell carcinomas without other typical phenotype of tuberous sclerosis. **J Clin Pathol.** 71(10), 936-943, 2018
9. Ito K, Mikami S, Tatsugami K, Masumori N, Shinohara N, Kondo T, Nakanishi S, Nagashima Y, Eto M, Kamba T, Kuroda N, Tomita Y, Matsuyama H, Onishi T, Tsushima T, Nakazawa H, Oya M, Ozono S, Naito S, Asano T; Clinical outcomes in patients with metastatic papillary renal-cell carcinoma: a multi-institutional study in Japan. **Clin Genitourin Cancer.** 16(6), e1201-1214, 2018
10. Kamba T. Bone-Targeted Treatment in CRPC management. **Hormone Therapy and Castration Resistance of Prostate Cancer.** Edited by Arai Y. and Ogawa O. Springer. pp.317-325, 2018
11. Baba M, Endoh M, Ma W, Toyama H, Hirayama A, Nishikawa K, Takubo K, Hano H, Hasumi H, Umemoto T, Hashimoto M, Irie N, Esumi C, Kataoka M, Nakagata N, Soga T, Yao M, Kamba T, Minami T, Ishii M, Suda T; Folliculin regulates osteoclastogenesis through metabolic regulation. **J Bone Miner Res.** 33(10), 1785-1798, 2018
12. Yoshimura Y, Taguchi A, Tanigawa S, Yatsuda J, Kamba T, Takahashi S, Kurihara H, Mukoyama M, Nishinakamura R; Manipulation of nephron-patterning signals enables selective induction of podocytes from human pluripotent stem cells. **J Am Soc Nephrol.** 2019 Jan 11. pii: ASN.2018070747. doi: 10.1681/ASN.2018070747

【和文総説 (原著論文、総説、著書など)】

1. 神波大己. ロボット手術におけるトラブルシューティング. *Japanese Journal of Endourology*, 29, 24-27, 2016
2. 神波大己. 去勢抵抗性前立腺癌に対する治療の実際. 日本臨牀増刊号 新前立腺癌学 (日本臨牀社), 632-639, 2016
3. 山口隆大, 神波大己. 進行直腸癌に対する泌尿器臓器合併切除 (膀胱・精囊・前立腺). *消化器外科*, 40, 1533-1538, 2017
4. 神波大己. 前立腺癌骨転移による骨関連事象とその予防. *泌尿器外科*, 30, 1511-1516, 2017
5. 村上洋嗣, 神波大己. Topics of RCC ~ 腎癌診療ガイドライン 2017 年版改定のポイント ~ . 4. 術前・術後補助薬物療法. *Year Book of RCC 2017 (メディカルレビュー社)*, 47-53, 2017
6. 神波大己. VIII. 腎癌の治療 3. 薬物療法 (3) サイトカイン療法. 日本臨牀増刊号 新腎・泌尿器癌上 (日本臨牀社), 301-305, 2017

眼科学講座

【研究プロジェクト名および概要】

1. 房水動態と創傷治癒におけるエピゲノムとファイブロサイトに着目した緑内障病態の研究
2. 線維柱帯細胞の可塑性に基づいた新治療開発に関する研究
3. 傷害網膜における組織再構築に関わる細胞間シグナルの解明とその制御機構の探索
4. 緑内障病態におけるメカノストレスと Hippo-YAP/TAZ シグナルの研究
5. 網膜色素上皮細胞とマイクログリアの相互作用と眼内増殖膜への影響に関する研究
6. 末梢血中を循環する fibrocyte の緑内障術後創傷治癒への関与の解明
7. 脈絡膜新生血管におけるマイクログリア亜種とアミロイド の関係に関する研究
8. 緑内障手術成績に関する研究
9. 網膜疾患の治療成績に関する研究
10. 家族性アミロイドポリニューロパチーに関する研究

【教職員および大学院学生】

【メールアドレス(任意)】

【研究プロジェクト】

| | | |
|-------------|--------|----------------|
| 教授 | 井上 俊洋 | 1 ~ 10 |
| 准教授 | 福島 美紀子 | 3, 9 |
| 講師 | 高橋 枝里 | 5, 7, 8 |
| 診療講師 | 伊藤 康裕 | 9 |
| 助教 | 有村 和枝 | 9 |
| | 瀧原 祐史 | 6, 8, 10 |
| | 藤本 智和 | 1, 2, 4, 6, 10 |
| | 小島 祥 | 1, 6, 8 |
| | 芳賀 彰 | 7, 9, 10 |
| | 中島 圭一 | 8 |
| | 福島 亜矢子 | 9 |
| 大学院学生(博士課程) | 松村 智世 | 1, 4, 8 |
| | 渡邊 文香 | 1, 4, 8 |
| | 江口 桃佳 | 5, 7 |
| | 渡邊 隆弘 | 8, 9, 10 |
| | 中村 健一 | 1, 6, 8, 9 |
| 技術補佐員 | 舩本 悠 | 1 ~ 10 |
| | 長谷 照美 | 1 ~ 10 |
| 事務補佐員 | 山村 小由里 | 研究の事務手続き |

【連絡先】 電話: 096-373-5247 Fax: 096-373-5249

【ホームページ】 <http://www2.kuh.kumamoto-u.ac.jp/ganka/>

【特殊技術・特殊装置】

1. リアルタイム PCR 解析装置
2. 蛍光顕微鏡
3. ルミノメーター
4. ex vivo 房水流出量測定装置
5. 多極所網膜電図計測装置 (VERIS)
6. 超音波画像診断装置
7. 広角眼底カメラ
8. 網膜光干渉断層計: OCT (CIRRUS, HRA)
9. 前眼部三次元画像解析装置

【英文論文】

1. Inoue T, Tanihara H. Ripasudil hydrochloride hydrate: targeting Rho kinase in the treatment of glaucoma. **Expert Opinion on Pharmacotherapy** 14:1-5, 2017. Review.
2. Shoji N, Arakaki Y, Nakamoto K, Yamamoto T, Kuwayama Y; Collaborative Bleb-related Infection Incidence and Treatment Study Group. Efficacy of predetermined therapeutic measures against bleb-related infection in the Collaborative Bleb-related Infection Incidence and Treatment Study. **Acta Ophthalmologica** 96:e229-e236, 2018.
3. Tsutsumi-Kuroda U, Inoue T, Futakuchi A, Shobayashi K, Takahashi E, Kojima S, Inoue-Mochita M, Fujimoto T, Tanihara H. Decreased MCP-1/CCR2 axis-mediated chemotactic effect of conjunctival fibroblasts after transdifferentiation into myofibroblasts. **Experimental Eye Research** 170:76-80, 2018.
4. Nakashima KI, Iwao K, Inoue T, Haga A, Tsutsumi T, Mochita MI, Fujimoto T, Tanihara H. Stimulation of the adenosine A3 receptor, not the A1 or A2 receptors, promote neurite outgrowth of retinal ganglion cells. **Experimental Eye Research** 170:160-168, 2018.
5. Yamagishi-Kimura R, Honjo M, Komizo T, Ono T, Yagi A, Lee J, Miyata K, Fujimoto T, Inoue T, Tanihara H, Nishida J, Uchida T, Araki Y, Aihara M. Interaction Between Pilocarpine and Ripasudil on Intraocular Pressure, Pupil Diameter, and the Aqueous-Outflow Pathway. **Investigative Ophthalmology & Visual Science** 59:1844-1854, 2018.
6. Inoue-Mochita M, Inoue T, Kojima S, Futakuchi A, Fujimoto T, Sato-Ohira S, Tsutsumi U, Tanihara H. Interleukin-6-mediated trans-signaling inhibits transforming growth factor- β signaling in trabecular meshwork cells. **Journal of Biological Chemistry** 293:10975-10984, 2018.
7. Futakuchi A, Inoue T, Wei FY, Inoue-Mochita M, Fujimoto T, Tomizawa K, Tanihara H. YAP/TAZ are essential for TGF- β 2-mediated conjunctival fibrosis. **Investigative Ophthalmology & Visual Science** 59:3069-3078, 2018.
8. Sakata R, Yoshitomi T, Iwase A, Matsumoto C, Higashide T, Shirakashi M, Aihara M, Sugiyama K, Araie M; Lower Normal Pressure Glaucoma Study Members in Japan Glaucoma Society. Factors associated with progression of Japanese open-angle glaucoma with lower normal intraocular pressure. **Ophthalmology**, in press.
9. Kawabata K, Shobayashi K, Iwao K, Takahashi E, Tanihara H, Inoue T. Efficacy and safety of Ex-PRESS[®] mini shunt surgery versus trabeculectomy for neovascular glaucoma: a retrospective comparative study. **BMC Ophthalmology** 19:75, 2019.

耳鼻咽喉科・頭頸部外科学講座

【研究プロジェクト名および概要】

1. 頭頸部腫瘍学

頭頸部腫瘍の診療と治療

頭頸部腫瘍における網羅的遺伝子解析

頭頸部腫瘍発症マウスモデルの作成

2. 喉頭科学

声帯癒痕生成機序の解明と新規薬物治療法の開発

エビデンスに基づく嚥下障害治療法の確立

筋衛星細胞を標的とした声帯麻痺に対する新規薬物治療法の開発

機能性発声障害と声帯振動解析

痙攣性発声障害の病態解明と新たな治療法の開発

3. 耳科学

遺伝性難聴の根本的治療法の開発

内耳発生メカニズムの解明

加齢性難聴の治療法の開発

ミトコンドリア異常による難聴の病態解明

【研究者および大学院生】 (研究プロジェクト)

| | | |
|------|---|------------------|
| 教授 | 折田 頼尚 | (研究の統括) |
| 准教授 | 熊井 良彦 | (1 - 、2 -) |
| 講師 | 村上 大造 | (1 -) |
| | 宮丸 悟 | (1 - 、2 -) |
| 助教 | 伊勢 桃子 | (1 - 、3 -) |
| | 西本 康兵 | (1 - 、2 -) |
| | 山田 卓生 | (1 - 、2 - 、3 -) |
| 特任助教 | 竹田 大樹 | (3 -) |
| | 宮本 祐亮 | |
| 医員 | 小川 晋太郎、伊東山 舞、 植田 寛之、岡崎 太郎、大徳 朋亮、廣田 薫瑠子、竹本 梨紗 志茂田 裕、眞方 洋明、蓑田 理彦、村上 瑛 | |
| 大学院生 | (博士2年) 齋藤 陽元、(1 -) | |

【連絡先】

TEL : 096 - 373 - 5255

【ホームページ】

<http://kumamoto-ent.com/>

【発表論文】

1. Marunaka H, Orita Y, Tachibana T, Miki K, Makino T, Yoshino T, Nishizaki K, Sato Y. Diffuse large B-cell lymphoma of the lacrimal sac arising from a patient with IgG4-related disease. *Mod Rheumatol* 2018; 28: 559-63
2. Tachibana T, Orita Y, Marunaka H, Makihara S, Hirai M, Gion Y, Ikegami K, Miki K, Makino T, Noyama Y, Komatsubara Y, Kimura M, Yoshino T, Nishizaki K, Sato Y. Neck metastasis in patients with T1-2 supraglottic cancer. *Auris Nasus Larynx* 2018; 45: 540-5
3. Tachibana T, Orita Y, Makino T, Komatsubara Y, Matsuyama Y, Naoi Y, Nakada M, Sato Y, Nishizaki K. Prognostic factors and importance of recognition of adult croup. *Acta Otolaryngol* 2018; 8: 1-5
4. Orita Y, Gion Y, Tachibana T, Ikegami K, Marunaka H, Makihara S, Yamashita Y, Miki K, Makino T, Akisada N, Akagi Y, Kimura M, Yoshino T, Nishizaki K, Sato Y. Laryngeal squamous cell papilloma is highly associated with human papillomavirus. *Jpn J Clin Oncol* 2018; 48: 350-5
5. Tachibana T, Kariya S, Orita Y, Nakada M, Makino T, Komatsubara Y, Matsuyama Y, Nishizaki K. Canal wall-down procedure with soft posterior meatal wall reconstruction in acquired cholesteatoma: focus on postoperative middle ear status. *Acta Otolaryngol* 2018; 138: 695-700
6. Makino T, Orita Y, Tachibana T, Marunaka H, Miki K, Akisada N, Akagi Y, Usui Y, Sato Y, Yoshino T, Nishizaki K. Computed tomography findings for diagnosing follicular thyroid neoplasms. *Acta Med Okayama* 2018; 72: 577-81
7. Computed Tomography Findings for Diagnosing Follicular Thyroid Neoplasms. Makino T, Orita Y, Tachibana T, Marunaka H, Miki K, Akisada N, Akagi Y, Usui Y, Sato Y, Yoshino T, Nishizaki K. *Acta Med Okayama*. 2018 Dec;72(6):577-581.
8. Significance of IgG4-positive cells in severe eosinophilic chronic rhinosinusitis. Koyama T, Kariya S, Sato Y, Gion Y, Higaki T, Haruna T, Fujiwara T, Minoura A, Takao S, Orita Y, Kanai K, Taniguchi M, Nishizaki K, Okano M. *Allergol Int*. 2018 Oct 10.

9. Canal wall-down procedure with soft posterior meatal wall reconstruction in acquired cholesteatoma: focus on postoperative middle ear status.
Tachibana T, Kariya S, Orita Y, Nakada M, Makino T, Komatsubara Y, Matsuyama Y, Naoi Y, Nishizaki K.
Acta Otolaryngol. 2018 Aug;138(8):695-700.
10. Laryngeal squamous cell papilloma is highly associated with human papillomavirus.
Orita Y, Gion Y, Tachibana T, Ikegami K, Marunaka H, Makihara S, Yamashita Y, Miki K, Makino T, Akisada N, Akagi Y, Kimura M, Yoshino T, Nishizaki K, Sato Y.
Jpn J Clin Oncol. 2018 Apr 1;48(4):350-355.
11. Kumai Y, Miyamoto T, Matsubara K, Samejima Y, Yamashita S, Ando Y, Orita Y.
Assessment of oropharyngeal swallowing dysfunction in myasthenia gravis patients presenting with difficulty in swallowing. *Auris Nasus Larynx.* 2018 Nov 1. pii: S0385-8146(18)30600-X.
12. Kumai Y, Miyamoto T, Matsubara K, Samejima Y, Yoshida N, Baba H, Orita Y.
Determining the Efficacy of the Chin-Down Maneuver Following Esophagectomy With Fiberoptic Endoscopic Evaluation of Swallowing. *Arch Phys Med Rehabil.* 2018 Nov 2. pii: S0003-9993(18)31442-4.
13. Engraftment of Human Pluripotent Stem Cell-derived Progenitors in the Inner Ear of Prenatal Mice.
Takeda H, Hosoya M, Fujioka M, Saegusa C, Saeki T, Miwa T, Okano H, Minoda R. *Sci Rep.* 2018 Jan 31;8(1):1941.
14. Primary Middle Ear Mucosal Melanoma: Case Report and Comprehensive Literature Review of 21 Cases of Primary Middle Ear and Eustachian Tube Melanoma.
Maxwell AK, Takeda H, Gubbels SP.
Ann Otol Rhinol Laryngol. 2018 Nov;127(11):856-863.
15. Challenges in Cell-Based Therapies for the Treatment of Hearing Loss.
Takeda H, Dondzillo A, Randall JA, Gubbels SP.
Trends Neurosci. 2018 Nov;41(11):823-837.

16. Tachibana T, Orita Y, Gion Y, Miki K, Ikegami K, Marunaka H, Makino T, Akagi Y, Akisada N, Tsumura M, Ito T, Yoshino T, Nishizaki K, Sato Y. Young adult patients with squamous cell carcinoma of the tongue strongly express p16 without human papillomavirus infection. *Acta Otolaryngol.* 2019 Feb 3:1-5.
17. Up-regulation of activation-induced cytidine deaminase and its strong expression in extra-germinal centres in IgG4-related disease. Gion Y, Takeuchi M, Shibata R, Takata K, Miyata-Takata T, Orita Y, Tachibana T, Yoshino T, Sato Y. *Sci Rep.* 2019 Jan 24;9(1):761.
18. Factors that prolong the duration of recovery in acute rhinosinusitis with orbital complications. Tachibana T, Kariya S, Orita Y, Nakada M, Makino T, Haruna T, Matsuyama Y, Komatsubara Y, Naoi Y, Sato Y, Nishizaki K. *Acta Otolaryngol.* 2019 Jan 10:1-5.
19. The effect of cochlear implants on vestibular-evoked myogenic potential responses and postural stability. Miwa T, Minoda R, Matsuyoshi H, Takeda H. *Auris Nasus Larynx.* 2019 Feb;46(1):50-57.

歯科口腔外科学講座

【研究プロジェクト名および概要】

I. 臨床研究

- I-1 口腔扁平上皮癌患者に対する化学放射線療法の効果についての研究
- I-2 口腔扁平上皮癌患者に対する術後補助化学療法についての研究
- I-3 口腔癌患者における放射線治療後のドライマウスについての研究
- I-4 口腔癌患者における化学放射線療法後の口腔粘膜炎についての研究
- I-5 口腔癌患者に対する免疫療法についての臨床的研究
- I-6 口腔癌患者の術後機能と機能回復についての研究
- I-7 歯周病と循環器疾患の関連性についての臨床的研究
- I-8 口腔フローラと全身疾患との関連性についての研究
- I-9 薬剤関連顎骨壊死に関する臨床的研究

II. 基礎研究

- 1 口腔扁平上皮癌の転移機構についての研究
 - A-1 リンパ節転移機構の解明
 - A-2 遠隔転移機構の解明
 - A-3 エピジェネティクス制御による転移機構について
 - A-4 がん微小環境と転移機構について
- 2 口腔扁平上皮癌の薬剤耐性についての研究
 - A-1 CDDP、5-FU、抗 EGFR 抗体に対する薬剤耐性機構について
 - A-2 エピジェネティクス制御による薬剤耐性機構について
 - A-3 がん微小環境と薬剤耐性機構について
- 3 口腔扁平上皮癌の放射線耐性についての研究
 - A-1 低酸素状態と放射線耐性機構について
 - A-2 エピジェネティクス制御による放射線耐性機構について
 - A-3 がん微小環境と放射線耐性機構について
- 4 口腔癌患者に対する免疫療法についての基礎的研究
ペプチドワクチン療法の効果の検討
- 5 放射線照射と唾液腺細胞の機能についての研究
- 6 歯周病と全身疾患の関連性についての基礎的研究

【研究者および大学院生】

教授 中山秀樹
准教授 吉田遼司
助教 福間大喜
助教 廣末晃之
助教 永田将士
特任助教 川原健太
医員 米田雅一
医員 松岡祐一郎
医員 小島拓
医員 鶴田未季
医員 坂田純基
医員 中嶋光

【メールアドレス】

hinakaya@kumamoto-u.ac.jp
ryoshida@kumamoto-u.ac.jp
daiki26@kumamoto-u.ac.jp
ahiro711@kumamoto-u.ac.jp
nagatama0213@gmail.com
k.k.ronbun@gmail.com
mameman1977@gmail.com
kokopelli205@gmail.com
kutamajiko@gmail.com
miki.3one9@gmail.com
j.sakata0510@gmail.com
ricken.hikaru@gmail.com

【研究プロジェクト】

研究の統括
I-1,2,3,6,9, -1,2,3
I-1,2,5,6, -4
I-1,2,7,8, 1,2,3,6
I-1,2,5,6, -2,5
I-1,2,7,9, -1,2,3,5
-1,2
1,2,3,6
I-2,5, -2,4
I-2,5, -2,4
I-1,2,3, -1,2,3
I-1,2,3, -1,2,3

医学教育部研究員 平山真弓 -1,2,3
大学院生（博士課程4年） 前城学 -1,2
大学院生（博士課程3年） 川口翔 -1,2,3
大学院生（博士課程3年） 山名啓介 -1,2,3
大学院生（博士課程3年） 永尾優果 I-8, -2,6
大学院生（博士課程3年） 郷原俊輔 -1,2,3
大学院生（博士課程3年） 八木田麻耶 -1,2,3
大学院生（博士課程2年） 竹下尚志 -1,2,3
大学院生（博士課程2年） 内藤久貴 -1,2
大学院生（博士課程2年） 岩本明日香 -4
大学院生（博士課程2年） 劉 隣 -1,2

【連絡先】 TEL:096-373-5288, FAX:096-373-5286

【ホームページ】 <http://www2.kuh.kumamoto-u.ac.jp/oralsurgery/>

【英文論文】

1. Tsuruta M, Ueda S, Yew PY, Fukuda I, Yoshimura S, Kishi H, Hamana H, Yatsuda J, Irie A, Senjyu S, Yuba E, Kamba T, Eto M, Nakayama H, and Nishimura Y.
Bladder cancer-associated cancer-testis antigen-derived long peptides encompassing both CTL and promiscuous HLA class II-restricted Th cell epitopes induced CD4+ T cells expressing converged T-cell receptor genes in vitro.
OncoImmunology 7(4):e1415687, 2018
2. Sakata J, Yamana K, Yoshida R, Matsuoka Y, Kawahara K, Arita H, Nakashima H, Nagata M, Hirose A, Kawaguchi S, Gohara S, Nagao Y, Hiraki A, Shinohara M, Toya R, Murakami R, Nakayama H.
Tumor budding as a novel predictor of occult metastasis in cT2N0 tongue squamous cell carcinoma.
Hum Pathol. 76: 1-8, 2018
3. Shinriki S, Jono H, Maeshiro M, Nakamura T, Guo J, Li JD, Ueda M, Yoshida R, Shinohara M, Nakayama H, Matsui H, Ando Y.
Loss of CYLD promotes cell invasion via ALK5 stabilization in oral squamous cell carcinoma.
J Pathol. 244(3):367-79, 2018
4. Hirata K, Nakaura T, Okuaki T, Kidoh M, Oda S, Utsunomiya D, Namimoto T, Kitajima M, Nakayama H, Yamashita Y.
Comparison of the image quality of turbo spin echo- and echo-planar diffusion-weighted images of the oral cavity.
Medicine (Baltimore) 97(19):e0447, 2018
5. Murakami R, Shiraishi S, Yoshida R, Sakata J, Yamana K, Hirose A, Uchiyama Y, Nakayama H, Yamashita Y.
Reliability of MRI-derived depth of invasion of oral tongue cancer
Academic Radiology pii: S1076-6332(18)30423-9, 2018
6. Yoneda M, Imamura R, Nitta H, Taniguchi K, Saito F, Kikuchi K, Ogi H, Tanaka T, Katabuchi H, Nakayama H, Imamura T.
Enhancement of cancer invasion and growth via the C5a-C5a receptor system: Implications for cancer promotion by autoimmune diseases and association with cervical cancer invasion.
Oncol Lett. 17(1)913-20, 2019 published online on Nov. 16, 2018
7. Nakashima H, Yoshida R, Hirose A, Kawahara K, Sakata J, Arita H, Yamamoto T, Toya R, Murakami R, Hiraki A, Shinohara M, Ito T, Kuwahara Y, Nakayama H.
Circulating miRNA-1290 as a potential biomarker for response to chemoradiotherapy and prognosis of patients with advanced oral squamous cell carcinoma: A single-center retrospective study.
Tumour Biol. 41(3):1010428319826853, 2019
8. Endocrine therapy-resistant breast cancer model cells are inhibited by soybean glyceollin I through Eleanor non-coding RNA. Yamamoto T, Sakamoto C, Tachiwana H, Kumabe M, Matsui T, Yamashita T, Shinagawa M, Ochiai K, Saitoh N, Nakao M.
Sci Rep. 8(1):15202, 2018
9. Sakata S, Matsuoka Y, Kawahara K, Kakiuchi Y, Takaki A, Hirose A, Yoshida R, Saeki S, Fujii K, Nakayama H.
Severe interstitial pneumonia associated with anti-PD-1 immune checkpoint antibody after talc slurry pleurodesis.
Respir Investig. 56(2):195-8, 2018
10. Nagata, M, Kusafuka K, Yoshida R, Kawahara K, Nakagawa Y, Nakamoto M, Shinohara M, Nakayama H.
Mucinous adenocarcinoma with signet ring cell features of the sublingual gland: A case report with an immunohistochemical analysis
Journal of Oral and Maxillofacial Surgery, Medicine, and Pathology 30(3):252-6, 2018
11. Segami N, Ogi H, Nakayama H, Nojima T.
Giant cell reparative granuloma of the mandibular condyle: A rare presentation and literature review
Oral and Maxillofacial Surgery Cases 4(4):130-4, 2018
12. Non-coding RNAs and chromatin domains.
Yamamoto T, Saitoh N.
Curr Opin Cell Biol. 58:26-33, 2019

皮膚病態治療再建学講座

【研究プロジェクト名および概要】

- . 膠原病および水疱症、脱毛症における各種サイトカインおよび細胞外マトリックスの病態への関与
- . 膠原病および皮膚悪性腫瘍における microRNA によるエピジェネティックな病態への関与
- . 膠原病および炎症性皮膚疾患におけるプロテオーム解析
- . 培養線維芽細胞のサイトカイン応答およびシグナル伝達の研究
- . 悪性黒色腫における新規腫瘍関連抗原の探索
- . 悪性黒色腫に対するイムノチェックポイント阻害剤のバイオマーカー探索
- . iPS 細胞由来の遺伝子改変マクロファージおよび樹状細胞による免疫療法の開発
- . 皮膚疾患における HSV1, 2, 6, 7, VZV, EBV の関与
- . 乾癬表皮における蛋白発現、ケモカインの解析
- . 皮膚悪性腫瘍におけるセンチネルリンパ節同定の研究
 - . 皮膚末梢血管分布の解析
 - . 皮膚血管腫、血管肉腫の遺伝子発現解析と病態解明
 - . 皮膚老化と血管新生、コラーゲン蛋白の代謝機構の解明
 - . 細胞の表皮細胞、血管内皮細胞、線維芽細胞への分化誘導
 - . 低酸素環境における血管肉腫悪性化機序の解明
- . 難治性皮膚潰瘍および重症下肢虚血に対する末梢血単核球移植療法の開発

【教職員および大学院学生】

【メールアドレス(任意)】

【研究プロジェクト】

| | | 研究の統括 |
|------|---------------------------|---------|
| 教授 | 尹 浩信 | |
| 准教授 | 福島 聡 | , , , |
| 講師 | 増口信一 | , , |
| 講師 | 牧野貴充 | , , |
| 助教 | 伊方敏勝 | , , |
| 助教 | 青井 淳 | , , |
| 助教 | 梶原一亨 | , , , , |
| 特任助教 | 宮下 梓(総合臨床研究部) | , , , |
| 特任助教 | 牧野雄成(免疫・アレルギー・血管病態学寄附講座) | , , , |
| 特任助教 | 中村香代(地域医療連携ネットワーク実践学寄附講座) | |
| 診療助手 | 本多教稔(形成再建科) | , , , , |
| 診療助手 | 中原智史(褥瘡対策室長) | |
| 診療助手 | 澤村創一郎(集中治療部) | |

医員

金澤早織、門久美菜、金丸央、渡邊千夏、西村祐紀、田中憲一郎、金子彰良、永野美和、松下晴香、清原佐央里、山村修司、古荘晶子、中島香織、江川清文、井上久仁子、永元英子、中山若菜、清原美穂子、林みゆき、石橋卓行、坂元亮子、大塚紗希、山下智香、宮村智裕、石松翔子、水橋覚

| | | |
|-------------|-------|---------|
| 大学院学生(博士課程) | 押川由佳 | , , |
| 大学院学生(博士課程) | 門久美菜 | , , , |
| 大学院学生(博士課程) | 坂元亮子 | , , , |
| 大学院学生(博士課程) | 島田秀一 | , , , , |
| 大学院学生(博士課程) | 大塚紗希 | , , , , |
| 大学院学生(博士課程) | 栗山春香 | , , , , |
| 大学院学生(博士課程) | 川野勇歩 | , , , , |
| 大学院学生(博士課程) | 木村俊寛 | , , , , |
| 大学院学生(博士課程) | 山下智香 | , , , , |
| 大学院学生(博士課程) | 石橋卓行 | , , , , |
| 大学院学生(博士課程) | 林 みゆき | , , , , |

大学院学生(博士課程) 宮村智裕
大学院学生(博士課程) 石松翔子
大学院学生(博士課程) 水橋 寛
大学院学生(博士課程) 草場雄道
大学院学生(博士課程) 金子彰良

【連絡先】 電話 : 096-373-5233 Fax : 096-373-5235

【ホームページ】 http://www2.kuh.kumamoto-u.ac.jp/derm_plas/

【特殊技術・特殊装置】

1. 凍結マイクロトーム LEICA CM3050S
2. 蛍光顕微鏡カールツァイツ 80DM
3. JMEC 社製 Qスイッチルビ-レーザー
4. Candela 社製 Vbeam色素レーザー
5. Qubit フルオロメーター(サーモフィッシャー)
6. Microplate reader (サーモフィッシャーMultiskanFC)
7. Bio clean bench (SANYO)
8. CO2 incubator (SANYO)
9. Thermal Cycler Dice™ Real Time System(TAKARA)
10. ChemiDoc XRS (BIO-RAD)
11. NanoDrop Lite (eppendorf)
12. Dynamic RI シンチグラフィ

【英文論文】

1. Urata K, Kajihara I, Myangat TM, Tasaki Y, Otsuka-Maeda S, Sawamura S, Kanazawa-Yamada S, Sakamoto R, Makino K, Aoi J, Igata T, Makino T, Masuguchi S, Fukushima S, Jinnin M, Ihn H. Overexpression of cyclin-dependent kinase 4 protein in extramammary Paget's disease. **J Dermatol.** 2019 Mar 21. [Epub ahead of print] (IF 2.788)
2. Yamada-Kanazawa S, Tasaki Y, Kajihara I, Sakamoto R, Maeda-Otsuka S, Ihn H. The expression of EpCAM in extramammary Paget's disease. **Intractable Rare Dis Res.** 2019 Feb;8(1):20-23.
3. Morita A, Okuyama R, Katoh N, Tateishi C, Masuda K, Komori T, Ogawa E, Makino T, Nishida E, Nishimoto S, Muramoto K, Tsuruta D, Ihn H. Efficacy and safety of adalimumab in Japanese patients with psoriatic arthritis and inadequate response to non-steroidal anti-inflammatory drugs (NSAIDs): A prospective, observational study. **Mod Rheumatol.** 2019 Mar 5:1-23. [Epub ahead of print] (IF 1.955)
4. Miyamura T, Egashira S, Yoshino Y, Sawatari M, Nishihara T, Ihn H. Papulonecrotic tuberculid after Bacillus Calmette-Guérin (BCG) vaccination with lung infiltration that mimics disseminated BCG infection. **J Dermatol.** 2019 Feb 27. [Epub ahead of print] (IF 2.788)
5. Yamada-Kanazawa S, Kajihara I, Kobayashi A, Watanabe C, Ihn H. Infliximab improved the refractory cutaneous involvement in a patient with dermatomyositis. **Dermatol Ther.** 2019 Feb 12:e12859. [Epub ahead of print] (IF 1.563)
6. Maeda-Otsuka S, Kajihara I, Tasaki Y, Yamada-Kanazawa S, Sakamoto R, Sawamura S, Masuzawa M, Masuzawa M, Amoh Y, Hoshina D, Abe R, Komohara Y, Ihn H. Hypoxia accelerates the progression of angiosarcoma through the regulation of angiosarcoma cells and tumor microenvironment. **J Dermatol Sci.** 2019 Feb;93(2):123-132.. Epub 2019 Jan 15.(IF 3.675)
7. Okamura K, Fukushima S, Yamashita J, Abe Y, Hayashi M, Hozumi Y, Ihn H, Suzuki T. Natural course of epidermolysis bullosa simplex with mottled pigmentation in a Japanese family with the p.P25L mutation in KRT5. **J Dermatol.** 2019 Jan 28. [Epub ahead of print] (IF 2.788)
8. Kanemaru H, Honda N, Kubo Y, Nishihara H, Onuma T, Sakai K, Fukushima S, Inoue Y, Honda Y, Ihn H. Case of cutaneous myoepithelioma managed with surgical resection without recurrence for 4 years. **J Dermatol.** 2019 Jan 23. [Epub ahead of print] No abstract available. (IF 2.788)
9. Sawamura S, Niimori D, Ihn H. A case of leg cellulitis caused by multidrug-resistant *Streptococcus pseudoporcinus*. **Intractable Rare Dis Res.** 2018 Nov;7(4):280-282.
10. Fujisawa Y, Funakoshi T, Nakamura Y, Ishii M, Asai J, Shimauchi T, Fujii K, Fujimoto M, Katoh N, Ihn H. Nation-wide survey of advanced non-melanoma skin cancers treated at dermatology departments in Japan. **J Dermatol Sci.** 2018 Dec;92(3):230-236. Epub 2018 Nov 3. (IF 3.675)
11. Takamatsu K, Nakane S, Suzuki S, Kosaka T, Fukushima S, Kimura T, Miyashita A, Mukaino A, Yamakawa S, Watanabe K, Jinnin M, Komohara Y, Ihn H, Ando Y. Immune checkpoint inhibitors in the onset of myasthenia gravis with hyperCKemia. **Ann Clin Transl Neurol.** 2018 Sep 23;5(11):1421-1427. (IF 4.649)
12. Egashira S, Jinnin M, Makino K, Ajino M, Shimozone N, Okamoto S, Tazaki Y, Hirano A, Ide M, Kajihara I, Aoi J, Harada M, Igata T, Masuguchi S, Fukushima S, Ihn H. Recurrent Fusion Gene ADCK4-NUMBL in Cutaneous Squamous Cell Carcinoma Mediates Cell Proliferation. **J Invest Dermatol.** 2019 Apr;139(4):954-957. (IF 6.448)

13. Takeichi T, Okuno Y, Kawamoto A, Inoue T, Nagamoto E, Murase C, Shimizu E, Tanaka K, Kageshita Y, Fukushima S, Kono M, Ishikawa J, Ihn H, Takahashi Y, Akiyama M. Reduction of stratum corneum ceramides in Neu-Laxova syndrome caused by phosphoglycerate dehydrogenase deficiency. **J Lipid Res.** 2018 Dec;59(12):2413-2420. (IF 4.505)
14. Umezawa Y, Torisu-Itakura H, Morisaki Y, ElMaraghy H, Nakajo K, Akashi N, Saeki H; Japanese Ixekizumab Study Group. Long-term efficacy and safety results from an open-label phase III study (UNCOVER-J) in Japanese plaque psoriasis patients: impact of treatment withdrawal and retreatment of ixekizumab. **J Eur Acad Dermatol Venereol.** 2019 Mar;33(3):568-576. (IF 4.287)
15. Kubo Y, Fukushima S, Inamori Y, Tsuruta M, Egashira S, Yamada-Kanazawa S, Nakahara S, Tokuzumi A, Miyashita A, Aoi J, Kajihara I, Tomita Y, Wakamatsu K, Jinnin M, Ihn H. Serum concentrations of HGF are correlated with response to anti-PD-1 antibody therapy in patients with metastatic melanoma. **J Dermatol Sci.** 2019 Jan;93(1):33-40. (IF 3.675)
16. Fujiwara H, Isogai Z, Irisawa R, Otsuka M, Kadono T, Koga M, Hirotsaki K, Asai J, Asano Y, Abe M, Amano M, Ikegami R, Ishii T, Isei T, Ito T, Inoue Y, Iwata Y, Omoto Y, Kato H, Kaneko S, Kanoh H, Kawakami T, Kawaguchi M, Kukino R, Kono T, Koderu M, Sakai K, Sakurai E, Sarayama Y, Shintani Y, Tanioka M, Tanizaki H, Tsujita J, Doi N, Nakanishi T, Hashimoto A, Hasegawa M, Hayashi M, Fujita H, Fujimoto M, Maekawa T, Matsuo K, Madokoro N, Motegi SI, Yatsushiro H, Yamasaki O, Yoshino Y, Pavoux AL, Tachibana T, Ihn H. Wound, pressure ulcer and burn guidelines - 2: Guidelines for the diagnosis and treatment of pressure ulcers, second edition. **J Dermatol.** 2018 Sep 8. [Epub ahead of print] (IF 2.788)
17. Yamashita T, Jinnin M, Makino K, Kajihara I, Aoi J, Masuguchi S, Fukushima S, Ihn H. Serum cytokine profiles are altered in patients with progressive infantile hemangioma. **Biosci Trends.** 2018 Sep 19;12(4):438-441. (IF 1.844)
18. Hirose M, Noguchi H, Yaguchi T, Matsumoto T, Hiruma M, Fukushima S, Ihn H. Onychomycosis caused by *Aspergillus subramanianii*. **J Dermatol.** 2018 Nov;45(11):1362-1366. (IF 2.788)
19. Noguchi H, Matsumoto T, Hiruma M, Asao K, Hirose M, Fukushima S, Ihn H. Topical efinaconazole: A promising therapeutic medication for tinea unguium. **J Dermatol.** 2018 Oct;45(10):1225-1228. (IF 2.788)
20. Tsukamoto H, Fujieda K, Miyashita A, Fukushima S, Ikeda T, Kubo Y, Senju S, Ihn H, Nishimura Y, Oshiumi H. Combined Blockade of IL6 and PD-1/PD-L1 Signaling Abrogates Mutual Regulation of Their Immunosuppressive Effects in the Tumor Microenvironment. **Cancer Res.** 2018 Sep 1;78(17):5011-5022. (IF 9.130)
21. Aoi J, Kajihara I, Masuguchi S, Fukushima S, Ihn H. Simple and effective modification of the axial frontonasal flap to prevent flap distortion. **J Dermatol.** 2019 Jan;46(1):e46-e47. (IF 2.788)
22. Sawamura S, Makino T, Johno T, Yamashita J, Niimori D, Fukushima S, Ihn H. Severe bacterial sepsis results in delayed diagnosis of tuberculous lymphadenitis in a rheumatoid arthritis patient treated with adalimumab. **Intractable Rare Dis Res.** 2018 May;7(2):138-140.
23. Tanoue Y, Toyoda T, Sun J, Mustofa MK, Tateishi C, Endo S, Motoyama N, Araki K, Wu D, Okuno Y, Tsukamoto T, Takeya M, Ihn H, Vaziri C, Tateishi S. Differential Roles of Rad18 and Chk2 in Genome Maintenance and Skin Carcinogenesis Following UV Exposure. **J Invest Dermatol.** 2018 Dec;138(12):2550-2557.(IF 6.448)
24. Miyamura T, Kajihara I, Makino K, Ihn H. Sweet's syndrome with laryngoparalysis due to laryngitis. **J Dermatol.** 2018 Nov;45(11):e295-e296. (IF 2.788)
25. Asano Y, Fujimoto M, Ishikawa O, Sato S, Jinnin M, Takehara K, Hasegawa M, Yamamoto T, Ihn H. Diagnostic criteria, severity classification and guidelines of localized scleroderma. **J Dermatol.** 2018 Jul;45(7):755-780. (IF 2.788)

26. Asano Y, Jinnin M, Kawaguchi Y, Kuwana M, Goto D, Sato S, Takehara K, Hatano M, Fujimoto M, Mugii N, Ihn H. Diagnostic criteria, severity classification and guidelines of systemic sclerosis. **J Dermatol.** 2018 Jun;45(6):633-691. (IF 2.788)
27. Kanamori S, Kajihara I, Kanazawa-Yamada S, Otsuka-Maeda S, Ihn H. Expression of aurora kinase A expression in dermatofibrosarcoma protuberans. **J Dermatol.** 2018 Apr;45(4):507-508. (IF 2.788)
28. Okiyama N, Asano Y, Hamaguchi Y, Jinnin M, Motegi SI, Koizumi H, Hasegawa M, Ishikawa O, Sato S, Takehara K, Yamamoto T, Fujimoto M, Ihn H. Impact of a new simplified disability scoring system for adult patients with localized scleroderma. **J Dermatol.** 2018 Apr;45(4):431-435. (IF 2.788)
29. Sawamura S, Jinnin M, Inoue K, Yamane K, Honda N, Kajihara I, Makino T, Masuguchi S, Fukushima S, Ihn H. Regulatory mechanisms of collagen expression by interleukin-22 signaling in scleroderma fibroblasts. **J Dermatol Sci.** 2018 Apr;90(1):52-59. (IF 3.675)
30. Shimada S, Fukushima S, Niimori D, Miyashita A, Setoyama H, Sasaki Y, Ihn H. Dabrafenib and trametinib combination therapy safely performed in a patient with metastatic melanoma after severe liver toxicity due to vemurafenib. **J Dermatol.** 2018 Jun;45(6):e157-e158. (IF 2.788)
31. Ikeda I, Igata T, Ihn H. First Aid for Skin Tears by Mini Patch Grafting from the Flap Edge. **J Emerg Med.** 2018 Apr;54(4):514-515. (IF 1.175)
32. Hasegawa M, Ishikawa O, Asano Y, Sato S, Jinnin M, Takehara K, Fujimoto M, Yamamoto T, Ihn H. Diagnostic criteria, severity classification and guidelines of lichen sclerosus et atrophicus. **J Dermatol.** 2018 Aug;45(8):891-897. (IF 2.788)
33. Jinnin M, Yamamoto T, Asano Y, Ishikawa O, Sato S, Takehara K, Hasegawa M, Fujimoto M, Ihn H. Diagnostic criteria, severity classification and guidelines of eosinophilic fasciitis. **J Dermatol.** 2018 Aug;45(8):881-890. (IF 2.788)
34. Sonoda-Shimada K, Kajihara I, Shimada S, Igata T, Jinnin M, Honda Y, Ihn H. Case of pigmented lipofibromatosis in a 27-year-old woman. **J Dermatol.** 2018 May;45(5):e128-e129. (IF 2.788)
35. Noda-Yamashita T, Kajihara I, Kidou M, Ihn H. Dyskeratosis congenita associated with congenital hypothyroidism. **J Dermatol.** 2018 Apr;45(4):e76-e77. (IF 2.788)

麻酔科学講座

[研究プロジェクト名および概要]

I. GPR103, GPR7,8 の侵害刺激伝達における役割

最近内因性のアゴニストが見つかった G タンパク共役型受容体である GPR103, GPR7,8 26RFa はその存在部位から侵害刺激伝達に関与していることが想定されている。我々は、ラットを用いた *in vivo* の系で、GPR103 及び GPR7 の生体内での役割、特に侵害刺激伝達における役割を検討している。また、GPR103 の内因性作動物質である QRFP の knockout mouse を用いて、QRFP の生体内での侵害刺激伝達における役割を検討している。

II. N-acetyl-aspartyl-glutamate (NAAG) の侵害刺激伝達における役割

NAAG は哺乳動物の中樞神経系に大量に存在する神経伝達物質である。しかし NAAG の役割は十分には解明されていない。我々は、NAAG 分解酵素阻害薬を用いて NAAG の侵害刺激伝達における役割を検討している。

III. 神経障害性疼痛に対する各種薬物の効果について

現在神経障害性疼痛に対する治療薬としてガイドラインに示されている薬物は多く存在するが、どのような種類の痛みにも有用であるかについては十分には検討されていない。神経障害性疼痛モデルを用い、ガイドラインに示されているプレガバリン、デュロキセチン、モルヒネ、トラマドールの有効性の差を明らかにすることにより、臨床での各種薬物による神経障害性疼痛治療指針の作成を目指している。

IV. 侵襲時におけるインスリン抵抗性と臓器障害 - 分子生物学的アプローチ -

現在主にストレス惹起インスリン抵抗性血管内皮障害に対する Ras 阻害剤(ファルネシルトランスフェラーゼ阻害剤)の治療効果についての検討を行っている。血管内皮障害はインスリン抵抗性における重要臓器障害の主要因である。ターゲットとなるシグナルについては Nitrosative stress、PI-3kinase eNOS 経路、NF- κ B を介した過剰な iNOS による NO 発生、Akt/PKB などがこれまで報告されてきた。一方 HMG-CoA 還元酵素阻害剤(スタチン)の lipid-lowering-independent effect がタンパクのファルネシル化抑制とされている。ファルネシルトランスフェラーゼ阻害剤で血管内皮障害を抑制できれば、さらにはスタチンの血管内皮障害治療への期待も広がることになる。重症患者モデルとして LPS マウスを用い、RAS 阻害剤である FTI-277 を腹腔内投与し、血管内皮障害への治療効果およびメカニズムについて、血管収縮弛緩反応、ウェスタンブロット法、免疫染色法にて解析を行っている。

- V. ペインクリニックにおける慢性疼痛患者と心理社会的要因 - 心身医学的アプローチ -
 従来からの薬物療法、神経ブロック治療に反応が乏しい慢性難治性疼痛患者に対して、心身医学的な評価と治療を行っている。生物学的モデルからみて、器質的病変は軽快・消失していると思われるのに、痛みを訴える患者をどうとらえればよいのであろうか。
 もちろん鎮痛薬への反応性が悪いものの中には、神経障害性疼痛患者が含まれているので、鎮痛補助薬の使用が効果的であろう。それらを鑑別除外していくと、心理社会的背景の関与が問題となる。痛みという言葉で、患者が何を訴えているのかを理解することが解決の糸口となる。痛みに対する破局的思考、恐怖回避モデル、抑うつ、心身症の中核概念であるアレキシサイミア（失感情症）、性格的な傾向としての強迫性、完璧主義、過剰適応、過活動（ペース配分の異常）、家族関係、虐待歴などから多面的に評価している。
- VI. 手術前には、誤嚥防止のため絶食・絶飲を行っている。しかしながら、どの程度の絶飲期間が必要であるかについては、定説がない。
 そこで、絶食にしたボランティアに対して蒸留水・砂糖水・電解質液などを投与し、胃からの排泄時間を、エコーを用いて検討している。
- VII. 筋弛緩薬の効果とスガマデックスによる拮抗
 肝機能低下の程度と筋弛緩薬の持続時間の相関を検討している。
 年齢と筋弛緩薬持続時間との相関関係を検討
 神経筋疾患患者における筋弛緩薬の効果持続時間
- VIII. 周術期の体温管理に関する研究
- IX. 麻酔器の基本的性能の検討、特に揮発性吸入麻酔薬の排出に関する研究

| [教職員及び大学院学生] | [メールアドレス] | [研究プロジェクト] |
|------------------|-------------------------|------------|
| 教授 山本 達郎 | yamyam@kumamoto-u.ac.jp | 研究の総括 |
| 講師 田代 雅文 | | V |
| 講師 杉田 道子 | | IV、VI |
| 講師 生田 義浩 | | VIII, IX |
| 助教 洲崎 祥子 | | IV |
| 助教 石村 達拓 | | VIII |
| 助教 野中 崇広 | | I, II, III |
| 特任助教 井上 由季子 | | VII |
| 大学院生(博士課程) 吉田 拓二 | | I, II, III |
| 大学院生(博士課程) 中村 真吾 | | I, II, III |

[連絡先] 電話：096-373-5275 FAX：096-363-9697

【 英文論文 】

1. Miyazaki R, Yamamoto T (2012) Efficacy of morphine, pregabalin, gabapentin and duloxetine on mechanical allodynia is different from that on neuroma pain in the rat neuropathic pain model. *Anesth Analg* 115,182-188.
2. Sugita M, Harada H, Yamamoto T (2012) Operative management of a patient with thyroid hormone resistance who underwent total thyroidectomy for thyroid cancer. *J Anesth.* 26,595-597.
3. Yamada T, Zuo D, Yamamoto T, Olszewski RT, Bzdega T, Moffett JR, Neale JH (2012) NAAG Peptidase Inhibition in the Periaqueductal Gray and Rostral Ventromedial Medulla Reduces Flinching in the Formalin Model of Inflammation. *Mol Pain* 8, 67.
4. Fujimoto M, Tanahira C, Nishi M, Yamamoto T (2013) In non-obese patients, duration of action of rocuronium is directly correlated with body mass index. *Can J Anaesth* 60,552-556
5. Yamamoto T. (2014) When will we get a new class of analgesic agent based on animal study data. *J. Anesth.* 28:323-324.
6. Shinozaki T, Yamada T, Nonaka T, Yamamoto T (2015) Acetaminophen and non-steroidal anti-inflammatory drugs interact with morphine and tramadol analgesia for the treatment of neuropathic pain in rats. *J Anesth* 29, 386-395
7. Fujimoto M, Terasaki S, Nishi M, Yamamoto T (2015) Response to rocuronium and its determinants in patients with myasthenia gravis: A case-control study. *Eur J Anaesthesiol* 32,672-80
8. Nonaka T, Hara M, Miyamoto C, Sugita M, Yamamoto T (2016) Comparison of the analgesic effect of intravenous acetaminophen with that of flurbiprofen axetil on post-breast surgery pain: A randomized controlled trial. *J Anesth* in press
9. Nonaka T, Yamada T, Ishimura T, Zuo D, Moffett JR, Neale JH, Yamamoto T (2017) A role for the locus coeruleus in the analgesic efficacy of N-acetylaspartylglutamate peptidase (GCPII) inhibitors ZJ43 and 2-PMPA.
10. Yoshida K, Nonaka T, Nakamura S, Araki M, Yamamoto T (2019) Microinjection of 26RFa, an endogenous ligand for the glutamine RF-amide peptide receptor (QRFP receptor), into the rostral ventromedial medulla (RVM), locus coeruleus (LC), and periaqueductal grey (PAG) produces an analgesic effect in rats. *Peptides*. 115:1-7. doi: 10.1016/j.peptides.2019.02.003.